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1. Preamble
Guidelines summarize and evaluate all available evidence at the
time of the writing process on a particular issue with the aim of
assisting physicians in selecting the best management strategies
for an individual patient, with a given condition, taking into
account the impact on outcome, as well as the risk–benefit ratio
of particular diagnostic or therapeutic means. Guidelines are no
substitutes but are complements for textbooks and cover the
ESC Core Curriculum topics. Guidelines and recommendations
should help physicians to make decisions in their daily practice.
However, the final decisions concerning an individual patient
must be made by the responsible physician(s).
A large number of Guidelines have been issued in recent years
by the European Society of Cardiology (ESC) as well as by other
societies and organizations. Because of the impact on clinical prac-
tice, quality criteria for the development of guidelines have been
established in order to make all decisions transparent to the
user. The recommendations for formulating and issuing ESC
Guidelines can be found on the ESC website (http://www.
escardio.org/guidelines-surveys/esc-guidelines/about/Pages/rules-
writing.aspx). ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
Members of this Task Force were selected by the ESC to
represent professionals involved with the medical care of patients
with this pathology. Selected experts in the field undertook a
Table 1 Classes of recommendations
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comprehensive review of the published evidence for diagnosis,
management, and/or prevention of a given condition according
to ESC Committee for Practice Guidelines (CPG) policy. A critical
evaluation of diagnostic and therapeutic procedures was per-
formed including assessment of the risk–benefit ratio. Estimates of
expected health outcomes for larger populations were included,
where data exist. The level of evidence and the strength of rec-
ommendation of particular treatment options were weighed and
graded according to pre-defined scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels filled in declara-
tions of interest forms of all relationships which might be perceived
as real or potential sources of conflicts of interest. These forms
were compiled into one file and can be found on the ESC
website (http://www.escardio.org/guidelines). Any changes in
declarations of interest that arise during the writing period must
be notified to the ESC and updated. The Task Force received its
entire financial support from the ESC without any involvement
from the healthcare industry.
The ESC CPG supervises and coordinates the preparation of
new Guidelines produced by Task Forces, expert groups, or con-
sensus panels. The Committee is also responsible for the endorse-
ment process of these Guidelines. The ESC Guidelines undergo
extensive review by the CPG and external experts. After appropri-
ate revisions, it is approved by all the experts involved in the Task
Force. The finalized document is approved by the CPG for
publication in the European Heart Journal.
The task of developing Guidelines covers not only the
integration of the most recent research, but also the creation of
educational tools and implementation programmes for the rec-
ommendations. To implement the guidelines, condensed pocket
guidelines versions, summary slides, booklets with essential mess-
ages, and electronic version for digital applications (smartphones,
etc.) are produced. These versions are abridged and, thus, if
needed, one should always refer to the full text version which is
freely available on the ESC website. The National Societies of
the ESC are encouraged to endorse, translate, and implement
the ESC Guidelines. Implementation programmes are needed
because it has been shown that the outcome of disease may be
favourably influenced by the thorough application of clinical
recommendations.
Surveys and registries are needed to verify that real-life daily
practice is in keeping with what is recommended in the guidelines,
thus completing the loop between clinical research, writing of
guidelines, and implementing them into clinical practice.
The guidelines do not, however, override the individual respon-
sibility of health professionals to make appropriate decisions in the
circumstances of the individual patients, in consultation with that
patient, and, where appropriate and necessary, the patient’s guar-
dian or carer. It is also the health professional’s responsibility to
verify the rules and regulations applicable to drugs and devices at
the time of prescription.
2. Introduction
2.1 Scope of the problem
Cardiovascular disease (CVD) due to atherosclerosis of the arter-
ial vessel wall and to thrombosis is the foremost cause of prema-
ture mortality and of disability-adjusted life years (DALYs) in
Europe, and is also increasingly common in developing countries.1
In the European Union, the economic cost of CVD represents
annually E192 billion1 in direct and indirect healthcare costs.
The main clinical entities are coronary artery disease (CAD),
ischaemic stroke, and peripheral arterial disease (PAD).
The causes of these CVDs are multifactorial. Some of these
factors relate to lifestyles, such as tobacco smoking, lack of physical
activity, and dietary habits, and are thus modifiable. Other risk
factors are also modifiable, such as elevated blood pressure, type
2 diabetes, and dyslipidaemias, or non-modifiable, such as age
and male gender.
These guidelines deal with the management of dyslipidaemias as
an essential and integral part of CVD prevention.
Prevention and treatment of dyslipidaemias should always be
considered within the broader framework of CVD prevention,
which is addressed in guidelines of the Joint European Societies’
Task forces on CVD prevention in clinical practice.2–5 The latest
version of these guidelines was published in 20075; an update
will become available in 2012.
These Joint ESC/European Atherosclerosis Society (EAS) guide-
lines on the management of dyslipidaemias are complementary to
the guidelines on CVD prevention in clinical practice and address
not only physicians [e.g. general practitioners (GPs) and cardiolo-
gists] interested in CVD prevention, but also specialists from
lipid clinics or metabolic units who are dealing with dyslipidaemias
that are more difficult to classify and treat.
2.2 Dyslipidaemias
Lipid metabolism can be disturbed in different ways, leading to
changes in plasma lipoprotein function and/or levels. This by
itself and through interaction with other cardiovascular (CV) risk
factors may affect the development of atherosclerosis.
Therefore, dyslipidaemias cover a broad spectrum of lipid
abnormalities, some of which are of great importance in CVD pre-
vention. Dyslipidaemias may be related to other diseases (second-
ary dyslipidaemias) or to the interaction between genetic
predisposition and environmental factors.
Elevation of total cholesterol (TC) and low-density
lipoprotein-cholesterol (LDL-C) has received most attention, par-
ticularly because it can be modified by lifestyle changes and drug
Table 2 Levels of evidence
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therapies. The evidence showing that reducing TC and LDL-C can
prevent CVD is strong and compelling, based on results from mul-
tiple randomized controlled trials (RCTs). TC and LDL-C levels
continue therefore to constitute the primary targets of therapy.
Besides an elevation of TC and LDL-C levels, several other
types of dyslipidaemias appear to predispose to premature
CVD. A particular pattern, termed the atherogenic lipid triad,
is more common than others, and consists of the co-existence
of increased very low density lipoprotein (VLDL) remnants man-
ifested as mildly elevated triglycerides (TG), increased small
dense low-density lipoprotein (LDL) particles, and reduced high-
density lipoprotein-cholesterol (HDL-C) levels. However, clinical
trial evidence is limited on the effectiveness and safety of inter-
vening in this pattern to reduce CVD risk; therefore, this pattern
or its components must be regarded as optional targets of CVD
prevention.
Dyslipidaemias may also have a different meaning in certain
subgroups of patients which may relate to genetic predisposition
and/or co-morbidities. This requires particular attention comp-
lementary to the management of the total CV risk.
3. Total cardiovasular risk
3.1 Total cardiovascular risk estimation
CV risk in the context of these guidelines means the likelihood of a
person developing an atherosclerotic CV event over a defined
period of time.
Rationale for total cardiovasular disease risk
All current guidelines on the prevention of CVD in clinical practice
recommend the assessment of total CAD or CV risk because, in
most people, atherosclerotic CVD is the product of a number of
risk factors. Many risk assessment systems are available, and have
been comprehensively reviewed, including Framingham, SCORE
(Systemic Coronary Risk Estimation), ASSIGN (CV risk estimation
model from the Scottish Intercollegiate Guidelines Network),
Q-Risk, PROCAM (Prospective Cardiovascular Munster Study),
and the WHO (World Health Organization).6,7
Most guidelines use risk estimation systems based on either the
Framingham or the SCORE projects.8,9
In practice, most risk estimation systems perform rather similarly
when applied to populations recognizably similar to that from
which the risk estimation system was derived,6,7 and can be
re-calibrated for use in different populations.6 The current joint
European Guidelines on CVD prevention in clinical practice5
recommend the use of the SCORE system because it is based
on large, representative European cohort data sets.
Risk charts such as SCORE are intended to facilitate risk
estimation in apparently healthy persons with no signs of clinical
or pre-clinical disease. Patients who have had a clinical event
such as an acute coronary syndrome (ACS) or stroke are at high
risk of a further event and automatically qualify for intensive risk
factor evaluation and management.
Thus, although refined later in this chapter, very simple
principles of risk assessment can be defined as follows5:
(1) Those with
† known CVD
† type 2 diabetes or type 1 diabetes with
microalbuminuria
† very high levels of individual risk factors
† chronic kidney disease (CKD)
are automatically at VERY HIGH or HIGH TOTAL
CARDIOVASCULAR RISK and need active management
of all risk factors.
(2) For all other people, the use of a risk estimation
system such as SCORE is recommended to estimate
total CV risk because many people have several risk
factors which, in combination, may result in unexpect-
edly high levels of total CV risk.
SCORE differs from earlier risk estimation systems in several
important ways, and has been modified somewhat for the
present guidelines.
The SCORE system estimates the 10 year risk of a first fatal
atherosclerotic event, whether heart attack, stroke, or other
occlusive arterial disease, including sudden cardiac death. Risk esti-
mates have been produced as charts for high and low risk regions
in Europe (see Figures 1 and 2). All International Classification of
Diseases (ICD) codes that could reasonably be assumed to be
atherosclerotic are included. Most other systems estimate CAD
risk only.
The new nomenclature in the 2007 guideline5 is that everyone
with a 10 year risk of CV death of ≥5% has an increased risk.
The reasons for retaining a system that estimates fatal as
opposed to total fatal + non-fatal events are that non-fatal
events are dependent on definition, developments in diagnostic
tests, and methods of ascertainment, all of which can vary, resulting
in very variable multipliers to convert fatal to total events. In
addition, total event charts, in contrast to those based on mor-
tality, cannot easily be re-calibrated to suit different populations.
Naturally, the risk of total fatal and non-fatal events is higher, and
clinicians frequently ask for this to be quantified. The SCORE data
indicate that the total CVD event risk is about three times higher
than the risk of fatal CVD for men, so that a SCORE risk of 5%
translates into a CVD risk of 15% of total (fatal plus non-fatal)
hard CVD endpoints; the multiplier is slightly higher in women
and lower in older persons.
Clinicians often ask for thresholds to trigger certain interven-
tions, but this is problematic since risk is a continuum and there
is no threshold at which, for example, a drug is automatically indi-
cated, and this is true for all continuous risk factors such as plasma
cholesterol or systolic blood pressure. Therefore, the targets that
are proposed in this document reflect this concept. A particular
problem relates to young people with high levels of risk factors;
a low absolute risk may conceal a very high relative risk requiring
intensive lifestyle advice. Therefore, a relative risk chart has been
added to the absolute risk charts to illustrate that, particularly in
younger persons, lifestyle changes can reduce relative risk substan-
tially as well as reducing the increase in absolute risk that will occur
with ageing (Figure 3).
Another problem relates to old people. In some age categories
the vast majority, especially of men, will have estimated CV death
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risks exceeding the 5–10% level, based on age (and gender) only,
even when other CV risk factor levels are relatively low. This could
lead to excessive usage of drugs in the elderly and should be
evaluated carefully by the clinician.
Charts are presented for TC. However, subsequent work on
the SCORE database10,11 has shown that HDL-C can contribute
substantially to risk estimation if entered as a separate variable as
opposed to the ratio. For example, HDL-C modifies risk at all
levels of risk as estimated from the SCORE cholesterol charts.10
Furthermore, this effect is seen in both genders and in all age
groups, including older women.11 This is particularly important at
levels of risk just below the 5% threshold for intensive risk modi-
fication; many of these subjects will qualify for intensive advice if
their HDL-C is low.10 Charts including HDL-C are available as
Addendum I to these guidelines on the ESC website (www.
escardio.org/guidelines). The additional impact of HDL-C on risk
estimation is illustrated in Figures 4 and 5. The electronic version
of SCORE, HeartScore, is being modified to take HDL-C into
account, and we recommend its use by using the www.
heartscore.org in order to increase the accuracy of the risk evalu-
ation. HeartScore will also include new data on body mass index
(BMI).
Figure 1 SCORE chart: 10 year risk of fatal cardiovascular disease (CVD) in populations at high CVD risk based on the following risk
factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal + non-fatal)
hard CVD, multiply by 3 in men and 4 in women, and slightly less in old people. Note: the SCORE chart is for use in people without overt CVD,
diabetes, chronic kidney disease, or very high levels of individual risk factors because such people are already at high risk and need intensive risk
factor advice.
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The role of a raised plasma TG level as a predictor of CVD has
been debated for many years. Fasting TG levels relate to risk in
univariate analyses, but the effect is attenuated by adjustment for
other factors, especially HDL-C. More recently, attention has
focused on non-fasting TG, which may be more strongly related
to risk independently of the effects of HDL-C.12 Currently TG
levels are not included in the risk charts. The effect of additional
risk factors such as high sensitivity C-reactive protein (hs-CRP)
and homocysteine levels was also considered. Their contribution
to absolute CV risk estimations for individual patients (in addition
to the older risk factors) is generally modest.
The impact of self-reported diabetes has been re-examined. The
impact of diabetes on risk appears greater than in risk estimation
systems based on the Framingham cohort, with relative risks of
5 in women and 3 in men.








Figure 2 SCORE chart: 10 year risk of fatal cardiovascular disease (CVD) in populations at low CVD risk based on the following risk factors:
age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal CVD to risk of total (fatal + non-fatal) hard
CVD, multiply by 3 in men and 4 in women, and slightly less in old people. Note: the SCORE chart is for use in people without overt
CVD, diabetes, chronic kidney disease, or very high levels of individual risk factors because such people are already at high risk and need inten-
sive risk factor advice.
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Figure 3 Relative risk chart.
Figure 4 Risk function without high-density lipoprotein-cholesterol (HDL-C) for women in populations at high cardiovascular disease risk,
with examples of the corresponding estimated risk when different levels of HDL-C are included.
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How to use the risk estimation charts
† The low risk charts should be considered for use in Belgium,
France, Greece, Italy, Luxembourg, Spain, Switzerland and
Portugal and also in countries which have recently experi-
enced a substantial lowering of the CV mortality rates (see
http://www.ehnheart.org/ (CVD statistics) for recent mor-
tality data). The high risk charts should be considered in
all other countries of Europe. NOTE that several countries
have undertaken national recalibrations to allow for time
trends in mortality and risk factor distributions. Such
charts are likely to represent current risk levels better.
† To estimate a person’s 10 year risk of CVD death, find the
table for their gender, smoking status, and age. Within the
table find the cell nearest to the person’s blood pressure
and TC. Risk estimates will need to be adjusted upwards
as the person approaches the next age category.
† Low risk persons should be offered advice to maintain their
low risk status. While no threshold is universally applicable,
the intensity of advice should increase with increasing risk.
† Relative risks may be unexpectedly high in young persons,
even if absolute risk levels are low. The relative risk chart
(Figure 3) may be helpful in identifying and counselling such
persons.
† The charts may be used to give some indication of the
effects of reducing risk factors, given that there will be a
time lag before risk reduces and that the results of random-
ized controlled trials in general give better estimates of
benefits. Those who stop smoking in general halve their risk.
† The presence of additional risk factors increases the risk
(such as low HDL-C, high TG).
Qualifiers
† The charts can assist in risk assessment and management but
must be interpreted in the light of the clinician’s knowledge
and experience and of the patient’s pre-test likelihood of
CVD.
† Risk will be overestimated in countries with a falling CVD
mortality, and underestimated in countries in which mor-
tality is increasing.
† At any given age, risk estimates are lower for women than
for men. This may be misleading since, eventually, at least
as many women as men die of CVD. Inspection of the
charts indicates that risk is merely deferred in women,
with a 60-year-old woman resembling a 50-year-old man
in terms of risk.
Risk will also be higher than indicated
in the charts in:
† Socially deprived individuals; deprivation drives many other
risk factors.
† Sedentary subjects and those with central obesity; these
characteristics determine many of the other aspects of risk
listed below.
† Individuals with diabetes: re-analysis of the SCORE database
indicates that those with known diabetes are at greatly
increased risk; five times higher in women and three times
higher in men.
† Individuals with low HDL-C or apolipoprotein A1 (apo A1),
increased TG, fibrinogen, homocysteine, apolipoprotein B
(apo B), and lipoprotein(a) [Lp(a)] levels, familial hypercho-
lesterolaemia (FH), or increased hs-CRP; these factors indi-
cate a higher level of risk in both genders, all age groups and
at all levels of risk. As mentioned above, supplementary
material (see Addendum I) illustrates the additional impact
of HDL-C on risk estimation.
† Asymptomatic individuals with preclinical evidence of
atherosclerosis, for example, the presence of plaques or
increased carotid intima–media thickness (CIMT) on
carotid ultrasonography.
† Those with impaired renal function.
† Those with a family history of premature CVD, which is con-
sidered to increase the risk by 1.7-fold in women and by
2.0-fold in men.
† Conversely, risk may be lower than indicated in those with
very high HDL-C levels or a family history of longevity.
3.2 Risk levels
A total CV risk estimate is part of a continuum. The cut-off
points that are used to define high risk are in part arbitrary
and based on the risk levels at which benefit is evident in clini-
cal trials. In clinical practice, consideration should be given to
practical issues in relation to the local healthcare and health
insurance systems.
Not only should those at high risk be identified and managed;
those at moderate risk should also receive professional advice
regarding lifestyle changes, and in some cases drug therapy will
be needed to control their plasma lipids.
In these subjects we should do all we realistically can to:
† prevent further increase in total CV risk,
† increase awareness of the danger of CV risk,
† improve risk communication, and
† promote primary prevention efforts.
Low risk people should be given advice to help them maintain this
status. Thus, the intensity of preventive actions should be tailored
to the patient’s total CV risk.
With these considerations one can propose the following levels
of total CV risk:
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1. Very high risk
Subjects with any of the following:
† Documented CVD by invasive or non-invasive testing (such as
coronary angiography, nuclear imaging, stress echocardiography,
carotid plaque on ultrasound), previous myocardial infarction
(MI), ACS, coronary revascularization [percutaneous coronary
intervention (PCI), coronary artery bypass graft (CABG)] and
other arterial revascularization procedures, ischaemic stroke,
PAD.
† Patients with type 2 diabetes, patients with type 1 diabetes with
target organ damage (such as microalbuminuria).
† Patients with moderate to severe CKD [glomerular filtration
rate (GFR) ,60 mL/min/1.73 m2).
† A calculated 10 year risk SCORE ≥10%.
2. High risk
Subjects with any of the following:
† Markedly elevated single risk factors such as familial dyslipidae-
mias and severe hypertension.
† A calculated SCORE ≥5% and ,10% for 10 year risk of fatal
CVD.
3. Moderate risk
Subjects are considered to be at moderate risk when their
SCORE is ≥1% and ,5% at 10 years. Many middle-aged subjects
belong to this risk category. This risk is further modulated by a
family history of premature CAD, abdominal obesity, physical
activity pattern, HDL-C, TG, hs-CRP, Lp(a), fibrinogen,
homocysteine, apo B, and social class.
4. Low risk
The low risk category applies to individuals with SCORE ,1%.
In Table 3 different intervention strategies are presented as a
function of the total CV risk and the LDL-C level.
Risk intervention in older people. The strongest driver of CVD risk
is age, which may be regarded as ‘exposure time’ to risk factors.
This raises the issue that Table 3 might suggest that most older
men in high risk countries who smoke would be candidates for
drug treatment, even if they have satisfactory blood pressure and
lipid levels. To date, this is not supported by trial evidence, and
the clinician is strongly recommended to use clinical judgement
in making therapeutic decisions in older people, with a firm
commitment to lifestyle measures such as smoking cessation in
the first instance.
4. Evaluation of laboratory lipid
and apolipoprotein parameters
Risk factor screening, including the lipid profile, may be considered
in adult men ≥40 years of age, and in women ≥50 years of age or
post-menopausal, particularly in the presence of other risk factors.
In addition, all subjects with evidence of atherosclerosis in any vas-
cular bed or with type 2 diabetes, irrespective of age, are regarded
as being at high risk; it is recommended to assess their lipid profile.
Individuals with a family history of premature CVD also deserve
early screening. Several other medical conditions are associated
Figure 5 Risk function without high-density lipoprotein-cholesterol (HDL-C) for men in populations at high cardiovascular disease risk, with
examples of the corresponding estimated risk when different levels of HDL-C are included.
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with premature CVD. Patients with arterial hypertension should be
carefully assessed for concomitant metabolic disorders and dyslipi-
daemias. Patients with central obesity, as defined for Europeans by
an increased waist circumference of ≥94 cm for men (90 cm for
Asian males) and ≥80 cm for women, or with a BMI ≥25 kg/m2
but ,30 kg/m2 (overweight), or ≥30 kg/m2 (obesity), should
also be screened—although one should recognize that the risk
for CVD increases more rapidly as the BMI increases, becoming
almost exponential from 27 kg/m2 upwards.
Autoimmune chronic inflammatory conditions such as rheuma-
toid arthritis, systemic lupus erythematosus (SLE), and psoriasis are
associated with increased CV risk. Patients with CKD (GFR
,60 mL/min/1.73 m2) are also at increased risk for CVD events
and should be screened for dyslipidaemias. Clinical manifestations
of genetic dyslipidaemias, including xanthomas, xanthelasmas, and
premature arcus cornealis, should be sought because they may
signal the presence of a severe lipoprotein disorder, especially
FH, the most frequent monogenic disorder associated with
premature CVD. Antiretroviral therapies may be associated with
accelerated atherosclerosis. It is also indicated to screen for dysli-
pidaemias in patients with PAD or in the presence of increased
CIMT or carotid plaques.
Finally, it is indicated to screen offspring of patients with severe
dyslipidaemia [FH, familial combined hyperlipidaemia (FCH) or
chylomicronaemia] and to follow them in specialized clinics if
affected. Similarly, screening for significant lipoprotein disorders
of family members of patients with premature CVD is
recommended.
The recommendations for lipid profiling in order to assess total
CV risk are presented in Table 4.
The baseline lipid evaluation suggested is: TC, TG, HDL-C, and
LDL-C, calculated with the Friedewald formula unless TG are
elevated (.4.5 mmol/L or greater than 400 mg/dL) or with a
direct method, non-HDL-C and the TC/HDL-C ratio.
Friedewald formula, in mmol/L: LDL-C ¼ TC - HDL-C - TG/2.2;
in mg/dL: LDL-C ¼ TC - HDL-C - TG/5.
Alternatively apo B and the apo B/apo A1 ratio can be used,
which have been found to be at least as good risk markers
compared with traditional lipid parameters.42
For these analyses, most commercially available methods are
well standardized. Methodological developments may cause
shifts in values, especially in patients with highly abnormal lipid
levels or in the presence of interacting proteins. Recent pro-
gression in dry chemistry has made possible analysis of lipids
on site in clinical practice. Among such available methods,
only certified and well standardized products should be used
whenever possible.
Fasting or non-fasting?
If possible, blood sampling should be made after 12 h fasting, but
this is requested only for the evaluation of TG, which is also
Table 3 Intervention strategies as a function of total CV risk and LDL-C level
*In patients with MI, statin therapy should be considered irrespective of LDL-C levels.13,14
aClass of recommendation
bLevel of evidence. References to level A: 15–41.
CV ¼ cardiovascular; LDL-C ¼ low-density lipoprotein-cholesterol; MI ¼ myocardial infarction.
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needed for the calculation of LDL-C with the Friedewald formula.
TC, apo B, apo A1, and HDL-C can be determined in non-fasting
samples.43 Fasting state is also essential if blood glucose is
measured in screening programmes.
Intraindividual variation
There is considerable intraindividual variation in plasma lipids. For
TC, a variation of 5–10% and for TG .20% has been reported,
particularly in those with hypertriglyceridaemia (HTG). This vari-
ation is to some extent due to analytical variation, but is also
due to environmental factors such as diet and physical activity
and a seasonal variation, with higher levels of TC and HDL-C
during the winter.
Lipid and lipoprotein analyses
Throughout this section it should be noted that most risk esti-
mation systems and virtually all drug trials are based on TC and
LDL-C, and that clinical benefit from using other measures includ-
ing apo B, non-HDL-C, and various ratios, while sometimes logical,
has not been proven. While their role is being established,
traditional measures of risk such as TC and LDL-C remain
robust and supported by a major evidence base. Furthermore, mul-
tiple clinical trials have established beyond all reasonable doubt
that, at least in high risk subjects, reduction of TC or LDL-C is
associated with a statistically and clinically significant reduction in
cardiovascular mortality. Therefore, TC and LDL-C remain the
primary targets recommended in these guidelines.
Total cholesterol
In screening programmes, TC is recommended to be used to
estimate total CV risk by means of the SCORE system. In the indi-
vidual case, however, TC may be misleading. This is especially so in
women who often have high HDL-C levels and in subjects with dia-
betes or the metabolic syndrome (MetS) who often have low
HDL-C levels. For an adequate risk analysis, at least HDL-C and
LDL-C should be analysed. Note that assessment of total risk
does not include patients with familial hyperlipidaemia (including
FH and FCH) or those with TC .8.0 mmol/L (310 mg/dL).
These patients are always at high risk and should receive special
attention.
Low-density lipoprotein-cholesterol
In most clinical studies LDL-C has been calculated using Friede-
wald’s formula (unless TG are elevated .4.5 mmol/L or more
than 400 mg/dL).
The calculated value of LDL-C is based on a number of
assumptions:
† Methodological errors may accumulate since the formula
necessitates three separate analyses of TC, TG, and HDL-C.
† A constant cholesterol/TG ratio in VLDL is assumed. With high
TG values (.4.5 mmol/L or more than 400 mg/dL), the
formula cannot be used.
† The use of Friedewald’s formula is not indicated when blood is
obtained under non-fasting conditions (class III C). Under these
conditions, non-HDL-C may be determined.
Despite its limitations, the calculated LDL-C is still widely used.
However, direct methods for determining LDL-C should be used
whenever available.
A number of commercially available methods for direct determi-
nation of LDL-C have appeared. The modern generation of these
methods have good reproducibility and specificity, and have the
advantage that the analysis is made in one step and they are not
sensitive to variations in TG levels to the same extent. Compari-
sons between calculated LDL-C and direct LDL-C show good
agreement; considering the limitations of calculated LDL-C,
direct LDL-C is recommended, although most trials have been
performed with calculated LDL-C.
A large amount of data is the basis for the current recommen-
dations, and internationally there is a good agreement between
different target levels. Non-HDL-C or apo B may give a better esti-
mate of the concentration of atherogenic particles, especially in
high risk patients with diabetes or MetS.
Non-high-density lipoprotein-cholesterol
Non-HDL-C is used as an estimation of the total number of
atherogenic particles in plasma [VLDL + intermediate-density lipo-
protein (IDL) + LDL] and relates well to apo B levels. Non-HDL-C
is easily calculated from TC minus HDL-C.
Non-HDL-C can provide a better risk estimation compared
with LDL-C, in particular in HTG combined with diabetes, the
MetS, or CKD. This is supported by a recent meta-analysis includ-
ing 14 statin trials, seven fibrate trials, and six nicotinic acid trials.44
Table 4 Recommendations for lipid profiling in order




BMI ¼ body mass index; CV ¼ cardiovascular; CVD ¼ cardiovascular disease.
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Most available assays are of high quality, but the method used
should be evaluated against the available reference methods and
controlled in international quality programmes.
Triglycerides
TG are determined by accurate and cheap enzymatic techniques. A
very rare error is seen in patients with hyperglycerolaemia where
falsely very high values for TG are obtained.
High TG are often associated with low HDL-C and high levels of
small dense LDL particles.
Recently studies have been published suggesting that non-fasting
TG may carry information regarding remnant lipoproteins associ-
ated with increased risk.12,45 How this should be used in clinical
practice is still debated.
Apolipoproteins
From a technical point of view there are advantages in the deter-
mination of apo B and apo A1. Good immunochemical methods
are available and easily run in conventional autoanalysers. The
analytical performance is good. The assay does not require
fasting conditions and is not sensitive to moderately high TG levels.
Apolipoprotein B. Apo B is the major apolipoprotein of the
atherogenic lipoprotein families VLDL, IDL, and LDL. The concen-
tration of apo B is a good estimate of the number of these particles
in plasma. This might be of special importance in the case of high
concentrations of small dense LDL. Apo B has been shown in
several prospective studies to be equal to LDL-C in risk prediction.
Apo B has not been evaluated as a primary treatment target in
statin trials, but several post-hoc analyses of statin trials suggest
that apo B may be not only a risk marker but also a better treat-
ment target than LDL-C.46 The major disadvantages of apo B are
that it is not included in algorithms for calculation of global risk,
and it has not been a pre-defined treatment target in controlled
trials. Recent data from a meta-analysis by the Emerging Risk
Factor Collaboration42 indicate that apo B does not provide any
benefit beyond non-HDL-C or traditional lipid ratios. Likewise,
apo B provided no benefit beyond traditional lipid markers in
people with diabetes in the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study.47 In contrast, in another
meta-analysis of LDL-C, non-HDL-C, and apo B, the latter was
superior as a marker of CV risk.48
Apoliprotein A1. Apo A1 is the major protein of HDL and pro-
vides a good estimate of HDL concentration. Each HDL particle
may carry several apo A1 molecules. Plasma apo A1 of
,120 mg/dL for men and ,140 mg/dL for women approximately
correspond to what is considered as low for HDL-C.
Apolipoprotein B/apolipoprotein A1 ratio, total cholesterol/high-density
lipoprotein-cholesterol ratio, and non-high-density lipoprotein-cholesterol/
high-density lipoprotein-cholesterol ratio
The different ratios give similar information. The ratio between apo
B and apo A1 has been used in large prospective studies as an indi-
cator of risk. Ratios between atherogenic lipoproteins and HDL-C
(TC/HDL-C, non-HDL-C/HDL-C, apo B/apo A1) are useful for
risk estimation, but for diagnosis and as treatment targets the
components of the ratio have to be considered separately.
Lipoprotein(a)
Lp(a) has been found in several studies to be an additional risk
marker.49 Lp(a) has properties in common with LDL but contains
a unique protein, apolipoprotein (a) [apo(a)], which is structurally
different from other apolipoproteins. The plasma level of Lp(a) is
to a major extent genetically determined. Several methods for
determination of Lp(a) are available, but standardization between
assays is needed as well as use of size-insensitive assays. Lp(a) is
generally expressed as total Lp(a) mass; however, it is rec-
ommended to express it as mmol/L (or mg/dL) of Lp(a)
protein.50 Plasma Lp(a) is not recommended for risk screening in
the general population; however, Lp(a) measurement should be
considered in people with high CVD risk or a strong family
history of premature atherothrombotic disease.51
Table 5 lists the recommendations for lipid analyses for screen-
ing for CVD risk and Table 6 the recommendations for lipid
analyses for characterization of dyslipidaemias; Table 7 gives the
Table 5 Recommendations for lipid analyses for
screening for CVD risk
aClass of recommendation.
bLevel of evidence.
Apo ¼ apolipoprotein; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular
disease; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density
lipoprotein-cholesterol; Lp ¼ lipoprotein; MetS ¼ metabolic syndrome; TC ¼
total cholesterol; TG ¼ triglyceride.
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recommendations for lipid analyses as treatment target in the
prevention of CVD.
Lipoprotein particle size
Lipoproteins are heterogeneous classes of particles, and a lot of
evidence suggests that the different subclasses of LDL and HDL
may bear different risks for atherosclerosis.54
Determination of small dense LDL may be regarded as an emer-
ging risk factor that may be used in the future54 but is not currently
recommended for risk estimation.55
Genotyping
Several genes have been associated with CVD. At present the use
of genotyping for risk estimation is not recommended. However,
studies suggest that in the future a panel of genotypes may be
used for identification of high risk subjects.56
For the diagnosis of specific genetic hyperlipidaemias, genotyp-
ing of apolipoprotein E (apo E) and of genes associated with FH
may be considered.
Apo E is present in three isoforms (apo E2, apo E3, and apo E4).
Apo E genotyping is primarily used for the diagnosis of dysbetalipo-
proteinaemia (apo E2 homozygosity) and is indicated in cases with
severe combined hyperlipidaemia.
Tools for genetic screening in families with FH are now available
and should be used in specialized clinics.57
5. Treatment targets
Treatment targets of dyslipidaemia are primarily based on results
from clinical trials. In nearly all lipid-lowering trials the LDL-C
level has been used as an indicator of response to therapy. There-
fore, LDL-C remains the primary target of therapy in most strat-
egies of dyslipidaemia management.
The most recent Cholesterol Treatment Trialists’ Collaboration
(CTT) meta-analysis of several trials involving .170 000 patients
confirmed the dose-dependent reduction in CVD with LDL-C
lowering.15
The overall guidelines on CVD prevention in clinical practice
strongly recommend modulating the intensity of the preventive
intervention according to the level of the total CV risk. Therefore,
the targets should be less demanding when the total CV risk
decreases from very high to high or moderate.
Table 7 Recommendations for lipid analyses as




Apo ¼ apolipoprotein; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular
disease; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density
lipoprotein-cholesterol; MetS ¼ metabolic syndrome; TC ¼ total cholesterol;
TG ¼ triglyceride.
Table 6 Recommendations for lipid analyses for
characterization of dyslipidaemias before treatment
aClass of recommendation.
bLevel of evidence.
Apo ¼ apolipoprotein; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular
disease; HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density
lipoprotein-cholesterol; Lp ¼ lipoprotein; MetS ¼ metabolic syndrome; TC ¼
total cholesterol; TG ¼ triglyceride.
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Every 1.0 mmol/L (40 mg/dL) reduction in LDL-C is associated
with a corresponding 22% reduction in CVD mortality and
morbidity.15
Extrapolating from the available data, an absolute reduction to an
LDL-C level ,1.8 mmol/L (less than 70 mg/dL) or at least a 50%
relative reduction in LDL-C provides the best benefit in terms of
CVD reduction.15 In the majority of patients, this is achievable with
statin monotherapy. Therefore, for patients with very high CV risk,
the treatment target for LDL-C is ,1.8 mmol/L (less than
70 mg/dL) or a ≥50% reduction from baseline LDL-C.
Target levels for subjects at high risk are extrapolated from
several clinical trials.15 An LDL-C level of ,2.5 mmol/L (less
than 100 mg/dL) should be considered for them. Secondary
targets of therapy in the high risk category are based on data extra-
polation; therefore, clinical judgement is required before a final
treatment plan is implemented. Clinicians again should exercise
judgement to avoid premature or unnecessary implementation of
lipid-lowering therapy. Lifestyle interventions will have an impor-
tant long-term impact on health, and the long-term effects of phar-
macotherapy must be weighed against potential side effects. For
subjects at moderate risk, an LDL-C target of ,3 mmol/L (less
than 115 mg/dL) should be considered.
Targets other than low-density lipoprotein-cholesterol
Because apo B levels have also been measured in outcome studies
in parallel with LDL-C, apo B can be substituted for LDL-C. Based
on the available evidence, apo B appears to be a risk factor at least
as good as LDL-C and a better index of the adequacy of
LDL-lowering therapy than LDL-C.46 Also, there now appears to
be less laboratory error in the determination of apo B than of
LDL-C, particularly in patients with HTG. However, apo B is not
presently being measured in all clinical laboratories. Clinicians
who are using apo B in their practice can do so; the apo B treat-
ment targets for subjects at very high or high total CV risk are
,80 and ,100 mg/dL, respectively.
The specific target for non-HDL-C should be 0.8 mmol/L
(30 mg/dL) higher than the corresponding LDL-C target; this
corresponds to the LDL-C level augmented by the cholesterol
fraction which is contained in 1.7 mmol/L (150 mg/dL) of TG,
which is the upper limit of what is recommended.
Adjusting lipid-lowering therapy to optimize one or more of the
secondary and optional targets may be considered in patients at
very high CV risk after achieving a target LDL-C (or apo B), but
the clinical advantages of this approach, with respect to patient
outcomes, remain to be addressed.
To date, no specific targets for HDL-C or TG levels have been
determined in clinical trials, although increases in HDL-C predict
atherosclerosis regression and low HDL-C is associated with
excess events and mortality in CAD patients, even when LDL-C
is lower than 1.8 mmol/L or 70 mg/dL. However, clinical trial
evidence is lacking on the effectiveness of intervening on these
variables to reduce CV risk further, and thus they must be
regarded as secondary and optional. The hypothesis of a specific
target for hs-CRP in secondary prevention is based on results
from pre-determined analyses of the Pravastatin Or Atorvastatin
Evaluation and Infection Therapy (PROVE-IT) and the A-to-Z
trials58 and from the Justification for the Use of statins in
Primary prevention: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) trial,59 which showed that patients who have reached
both an LDL-C level ,2.0 mmol/L (less than 80 mg/dL) and an
hs-CRP level ,2.0 mg/L had the lowest CVD event rate. Presently,
hs-CRP as a secondary target of therapy is not recommended for
everybody; based on available data, however, it may be useful in
people close to the high risk category to better stratify their
total CV risk. Clinicians should use clinical judgement when consid-
ering further treatment intensification in secondary prevention or
in high risk primary prevention.
Table 8 lists the recommendations for treatment targets for
LDL-C.
If non-HDL-C is used, the targets should be ,2.6 mmol/L (less
than 100 mg/dL) and ,3.3 mmol/L (less than 130 mg/dL) in
those at very high and high total CV risk, respectively (class IIa B46).
If apo B is available, the targets are ,80 mg/dL and ,100 mg/dL
in those at very high and high total CV risk, respectively (class IIa B46).
6. Lifestyle modifications to
improve the plasma lipid profile
The role of nutrition in the prevention of CVD has been exten-
sively reviewed.60–62 There is strong evidence showing that





CKD ¼ chronic kidney disease; CV ¼ cardiovascular; CVD ¼ cardiovascular
disease; LDL-C ¼ low-density lipoprotein-cholesterol.
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dietary factors may influence atherogenesis directly or through
effects on traditional risk factors such as lipid levels, blood
pressure, or glucose levels.
Results from RCTs relating dietary pattern to CVD have been
reviewed.60 Some interventions resulted in significant CVD pre-
vention, whereas others did not. Most evidence linking nutrition
to CVD is based on observational studies and on investigations
of the effects of dietary changes on lipid levels. In this section,
the influence of lifestyle changes and of functional foods on
lipoproteins is considered and summarized in Table 9.
6.1 The influence of lifestyle on total
cholesterol and low-density
lipoprotein-cholesterol levels
Dietary saturated fatty acids (SFAs) are the dietary factor with the
strongest impact on LDL-C levels (0.02–0.04 mmol/L or 0.8–
1.6 mg/dL of LDL-C increase for every additional 1% energy
coming from saturated fat).63
Stearic acid, in contrast to other SFAs (lauric, myristic, and
palmitic), does not increase TC levels.
Trans unsaturated fatty acids can be found in limited amounts
(usually ,5% of total fat) in dairy products and in meats from
ruminants. ‘Partially hydrogenated fatty acids’ of industrial origin
represent the major source of trans fatty acids in the diet; the
average consumption of trans fatty acids in western countries is
between 2 and 5% of the total energy intake. Quantitatively,
dietary trans fatty acids have a similar raising effect on LDL-C to
that of SFAs.64
If 1% of the dietary energy derived from SFAs is replaced by
monounsaturated fatty acids (MUFAs), LDL-C decreases by
0.041 mmol/L (1.6 mg/dL); if replaced by n-6 polyunsaturated
fatty acids (PUFAs) the decrease would be 0.051 mmol/L
(2.0 mg/dL); and if replaced by carbohydrate it would be
0.032 mmol/L (1.2 mg/dL).63 PUFAs of the n-3 series have no
direct hypocholesterolaemic effect; however, habitual fish con-
sumption is associated with a reduced CV risk that is mostly inde-
pendent of any effect on plasma lipids. When consumed in
pharmacological doses (.2 g/day) the effect of n-3 PUFAs on
LDL-C levels is either neutral or a slight increase with a concomi-
tant decrease of TG.63 A positive relationship exists between
dietary cholesterol and CAD mortality, which is partly indepen-
dent of TC levels. Several experimental studies on humans have
evaluated the effects of dietary cholesterol on cholesterol absorp-
tion and lipid metabolism and have revealed marked variability
among individuals.66,82 Dietary carbohydrate is ‘neutral’ on
LDL-C; therefore, carbohydrate-rich foods represent one of the
possible options to replace saturated fat in the diet.83 Dietary
fibre (particularly of the soluble type), which is present in
legumes, fruit, vegetables, and wholemeal cereals, has a direct
hypocholesterolaemic effect.65 Therefore, carbohydrate foods
rich in fibres represent an optimal dietary substitute for saturated
fat to maximize the effects of the diet on LDL-C levels and to mini-
mize possible untoward effects of a high carbohydrate diet on
other lipoproteins.65
Body weight reduction also influences TC and LDL-C, but the
magnitude of the effect is rather small; in grossly obese subjects
a drop in LDL-C concentration of 0.2 mmol/L (8 mg/dL) is
observed for every 10 kg of weight loss. Even smaller is the
reduction of LDL-C levels induced by regular physical exercise.68,70
In Table 9 dietary recommendations to lower TC and LDL-C are
summarized; given the cultural diversity of diets in Europe, these
recommendations should be translated into practical cooking
recipes, taking into account local habits and socioeconomic factors.
6.2 The influence of lifestyle
on triglyceride levels
A high monounsaturated fat diet significantly improves insulin sen-
sitivity compared with a high saturated fat diet.84 This goes in par-
allel with a reduction in TG levels, particularly in the post-prandial
period.
Another dietary effect on TG is observed with a high dosage of
long chain n-3 PUFAs; however, a dietary approach based exclu-
sively on natural foods will seldom reach an intake adequate to
achieve a clinically significant effect. To this aim either pharmaco-
logical supplements or foods artificially enriched with n-3 PUFAs
may be utilized.84
In people with severe HTG with chylomicrons present, also in
the fasting state, it is appropriate to reduce the total amount of
dietary fat as much as possible (,30 g/day); in these patients,
the use of medium chain TG that avoid the formation of chylomi-
crons may be considered since they are directly transported and
metabolized in the liver.
Glucose and lipid metabolism are strongly related, and any
perturbation of carbohydrate metabolism induced by a high carbo-
hydrate diet will also lead to an increase in TG concentrations. The
greater and more rapid this perturbation is, the more pronounced
are the metabolic consequences. Most detrimental effects of a high
carbohydrate diet could be minimized if carbohydrate digestion
and absorption were slowed down. The glycaemic index permits
identification, among carbohydrate-rich foods, of those with ‘fast’
and ‘slow’ absorption. In particular the detrimental effects of a
high carbohydrate diet on TG occur mainly when
carbohydrate-rich foods with a high glycaemic index/low fibre
content are consumed, while they are much less prominent if
the diet is based largely on fibre-rich, low glycaemic index foods.85
The beneficial effects on plasma lipid metabolism induced by low
glycaemic index/high fibre foods cannot be automatically extrapo-
lated to foods in which fructose (a sugar with a low glycaemic
index) represents the major source of carbohydrates. In contrast,
dietary fructose contributes to TG elevations; these effects are
dose dependent and become clinically relevant when the intake
is .10% energy daily—with a habitual fructose consumption
between 15 and 20% of the energy intake, plasma TG increases
as much as 30–40%. Sucrose, a disaccharide containing glucose
and fructose, represents an important source of fructose in the
diet.76
Weight reduction improves insulin sensitivity and decreases TG
levels. In many studies the reduction of TG levels due to weight
reduction is between 20 and 30%; this effect is usually preserved
as long as weight is not regained.70
Alcohol intake has a major negative impact on TG levels. While
in individuals with HTG even a small amount of alcohol can induce
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a further elevation of TG concentrations, in the general population
alcohol exerts detrimental effects on TG levels only if the intake
exceeds what is considered a moderate consumption (up to 1–2
drinks/day corresponding to 10–30 g/day).74
6.3 The influence of lifestyle on
high-density lipoprotein-cholesterol levels
SFAs increase HDL-C levels in parallel with LDL-C; in contrast,
trans fatty acids reduce the former and increase the latter.
Table 9 Impact of specific lifestyle changes on lipid levels
+++ ¼ general agreement on the effects on lipid levels.
++ ¼ less pronounced effects on lipid levels; weight of evidence/opinion is in favour of efficacy.
+ ¼ conflicting evidence; efficacy is less well established by evidence/opinion.
– ¼ not effective and/or uncertainties regarding safety.
HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density lipoprotein-cholesterol; TG ¼ triglyceride.
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MUFA consumption as a replacement for SFAs has a small or no
effect on HDL-C; n-6 PUFAs induce a slight decrease. In general,
n-3 fatty acids have limited (,5%) effect on HDL-C levels.63,86
Increased carbohydrate consumption, as isocaloric substitution
for fat, is associated with a significant decrease in HDL-C
(0.1 mmol/L or 4 mg/dL for every 10% energy substitution).
However, when the carbohydrate-rich foods have a low glycaemic
index and a high fibre content, the reduction of HDL-C is either
not observed or is very small.63,87 Usually a high fructose/sucrose
intake is associated with a more pronounced decrease of HDL-C.
Moderate ethanol consumption (up to 20–30 g/day in men and
10–20 g/day in women) is associated with increased HDL-C levels
as compared with abstainers.86
Weight reduction has a beneficial influence on HDL-C levels: a
0.01 mmol/L (0.4 mg/dL) increase is observed for every kg
decrease in body weight when weight reduction has stabilized.
Aerobic physical activity corresponding to a total energy expendi-
ture of between 1500 and 2200 kcal/week, such as 25–30 km of
brisk walking per week (or any equivalent activity) may increase
HDL-C levels by 0.08–0.15 mmol/L (3.1–6 mg/dL).77 Smoking
cessation may also contribute to HDL-C elevation.5,81
6.4 Dietary supplements and functional
foods active on plasma lipid values
Innovative nutritional strategies to improve dyslipidaemias have
been developed; they are based either on changing some ‘risky’
dietary components or on encouraging the consumption of specifi-
cally targeted ‘healthy’ functional foods and/or dietary sup-
plements; these so-called ‘nutriceuticals’ can be used either as
alternatives or in addition to lipid-lowering drugs.69
Nutritional evaluation of functional foods includes not only the
search for the clinical evidence of beneficial effects relevant to
improved health or reduction of disease risk, but also the demon-
stration of good tolerability and the absence of major undesirable
effects. The substantiation of health claims relevant for each food
should be based on results from intervention studies in humans
that are consistent with the proposed claims.88
Overall, the available evidence on functional foods so far ident-
ified in this field is lacking; the major gap is the absence of diet-
based intervention trials of sufficient duration to be relevant for
the natural history of dyslipidaemia and CVD.
Phytosterols
The principal phytosterols are sitosterol, campesterol, and stigmas-
terol, and they occur naturally in vegetable oils and, in smaller
amounts, in vegetables, fresh fruits, chestnuts, grains, and
legumes. The dietary intake of plant sterols ranges between an
average of 250 mg/day in Northern Europe to 500 mg/day in
Mediterranean countries. Phytosterols compete with cholesterol
for intestinal absorption, thus modulating TC levels.
Phytosterols have been added to spreads and vegetable oils (func-
tional margarine, butter, and cooking oils) as well as yoghurt and
other foods; however, food matrices do not significantly influence
the cholesterol-lowering efficacy of phytosterols at equivalent
doses. The daily consumption of 2 g of phytosterols can effectively
lower TC and LDL-C by 7–10% in humans, with little or no effect
onHDL-CandTG levelswhen consumedwith themainmeal.67Cur-
rently there are no data available indicating that cholesterol lowering
through plant sterol ingestion results in prevention of CVD. Long-
term surveillance is also needed to guarantee the safety of the
regular use of phytosterol-enriched products. The possible decrease
in carotenoid and fat-soluble vitamin levels by sterols/stanols can be
prevented with a diet rich in these nutrients.89
Soy protein
Soy protein has a modest LDL-C-lowering effect. Soy foods can be
used as a plant protein substitute for animal protein foods high in
SFAs, but expected LDL-C lowering may be modest (3–5%) and
most likely in subjects with hypercholesterolaemia.90
Dietary fibre
Available evidence consistently demonstrates a TC- and
LDL-C-lowering effect of water-soluble fibre from oat bran,
b-glucan, and psyllium. Foods enriched with these fibres are well
tolerated, effective, and recommended for LDL-C lowering at a
daily dose of 5–15 g/day soluble fibre.91
n-3 unsaturated fatty acids
Supplementation with 2–3 g/day of fish oil (rich in long chain n-3 fatty
acids) can reduce TG levels by 25–30% in both normolipidaemic and
hyperlipidaemic individuals.a-Linolenic acid (amedium chain n-3 fatty
acid present in chestnuts, some vegetables, and some seed oils) is less
effective on TG levels. Long chain n-3 PUFAs also reduce the post-
prandial lipaemic response. Long chain n-3 PUFAs, at doses of 3 g/
day given as supplements, may increase LDL-C by 5% in severely
hypertriglyceridaemic patients.85 However, a low dose supplemen-
tation of a margarine with n-3 PUFAs (400 mg/day) or a-linolenic
acid (2 g/day) did not significantly reduceTG levels in anRCT involving
4837 post-MI patients; neither did this supplementation reduce the
rate of major CV events.92
Policosanol and red yeast rice
Policosanol is a natural mixture of long chain aliphatic alcohols
extracted primarily from sugarcane wax.93 Studies show that poli-
cosanol from sugarcane, rice, or wheat germ has no significant
effect on LDL-C, HDL-C, TG, apo B, Lp(a), homocysteine,
hs-CRP, fibrinogen, or blood coagulation factors.94
‘Red yeast rice’ (RYR) is a source of fermented pigment used in
China as a food colourant and flavour enhancer for centuries.
Possible bioactive effects of RYR are related to a statin-like mech-
anism [inhibition of hydroxymethylglutaryl-coenzyme A
(HMG-CoA) reductase]. Different commercial preparations of
RYR have different concentrations of monacolins, the bioactive
ingredients, and lower TC and LDL-C,71 but the long-term safety
of the regular consumption of these products is not fully documen-
ted. In one RCT from China in patients with CAD, a partially pur-
ified extract of RYR reduced recurrent events by 45%.72
6.5 Lifestyle recommendations
Body weight and physical activity
Since overweight, obesity, and central obesity often contribute to
dyslipidaemia, caloric intake should be reduced and energy
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expenditure increased in those with excessive weight and/or
abdominal adiposity. Overweight is defined as a BMI ≥25 to
,30 kg/m2 and obesity as a BMI ≥30 kg/m2. Criteria for central
obesity as defined by the International Diabetes Federation are
given in Table 10.95 Body weight reduction, even if modest (5–10%
of basal body weight), improves lipid abnormalities and favourably
affects the other CV risk factors often present in dyslipidaemic indi-
viduals. Weight reduction can be achieved by decreasing the con-
sumption of energy-dense foods, inducing a caloric deficit of 300–
500 kcal/day. To be effective in the long run, this advice should be
incorporated into structured, intensive lifestyle education pro-
grammes. In order to facilitate maintenance of body weight close
to the target, it is always appropriate to advise people with dyslipi-
daemia to engage in regular physical exercise of moderate intensity.5
Modest weight reduction and regular physical exercise of moderate
intensity is very effective in preventing type 2 diabetes and improving
all the metabolic abnormalities and the CV risk factors clustering
with insulin resistance, often associated with abdominal adiposity.
Physical activity should be encouraged, aiming at regular physical
exercise for at least 30 min/day every day.
Dietary fat
The recommended total fat intake is between 25 and 35% of cal-
ories for adults.96,97 For most individuals, a wide range of intakes is
acceptable and will depend upon individual preferences and
characteristics. Fat intakes that exceed 35% of calories are gener-
ally associated with increased intakes of both saturated fat and cal-
ories. Conversely, a low intake of fats and oils increases the risk of
inadequate intakes of vitamin E and of essential fatty acids, and may
contribute to unfavourable changes in HDL.5
The type of fat intake should predominantly come from sources of
MUFAs and both n-6 and n-3 PUFAs. To improve plasma lipid levels,
saturated fat intake should be lower than 10% of the total caloric
intake. The optimal intake of SFAs should be further reduced
(,7% of energy) in the presence of hypercholesterolaemia. The
intake of n-6 PUFAs should be limited to ,10% of the energy
intake, both to minimize the risk of lipid peroxidation of plasma lipo-
proteins and to avoid any clinically relevant HDL-C decrease.5
Observational evidence supports the recommendation that
intake of fish and n-3 fatty acids from plant sources (a-linolenic
acid) may reduce the risk of CV death and stroke but has no
major effects on plasma lipoprotein metabolism. Supplementation
with pharmacological doses of n-3 fatty acids (.2–3 g/day)
reduces TG levels, but a higher dosage may increase LDL-C; not
enough data are available to make a recommendation regarding
the optimal n-3/n-6 fatty acid ratio.98
The cholesterol intake in the diet should ideally be ,300 mg/day.
Limited consumption of foods made with processed sources of
trans fats provides the most effective means of reducing intake of
trans fats below 1% of energy. Because the trans fatty acids pro-
duced in the partial hydrogenation of vegetable oils account for
.80% of total intake, the food industry has an important role in
decreasing the trans fatty acid content of the food supply.
Dietary carbohydrate and fibre
Carbohydrate intake may range between 45 and 55% of total
energy. Consumption of vegetables, legumes, fruits, nuts, and
wholegrain cereals should be particularly encouraged, together
with all the other foods rich in dietary fibre with a low glycaemic
index. A fat-modified diet that provides 25–40 g of total dietary
fibre, including at least 7–13 g of soluble fibre, is well tolerated,
effective, and recommended for plasma lipid control; conversely,
there is no justification for the recommendation of a very low
carbohydrate diet.
Intake of sugars should not exceed 10% of total energy (in
addition to the amount present in natural foods such as fruit and
dairy products); more restrictive advice concerning sugars may
be useful for those needing to lose weight or with high plasma
TG values. Soft drinks should be used with moderation by the
general population and should be drastically limited in those indi-
viduals with elevated TG values.
Alcohol and smoking
Moderate alcohol consumption (up to 20–30 g/day for men and
10–20 g/day for women) is acceptable for those who drink alco-
holic beverages, provided that TG levels are not elevated.
Smoking cessation has clear benefits on the overall CV risk and
specifically on HDL-C.5
Dietary supplements and functional foods
There are many functional foods and dietary supplements that are
currently promoted as beneficial for people with dyslipidaemia or
for reducing the risk of CVD. Some of these products have been
shown to have potentially relevant functional effects but have not
been tested in long-term clinical trials, and should therefore be uti-
lized only when the available evidence clearly supports their ben-
eficial effects on plasma lipid values and their safety. Based on the
available evidence, foods enriched with phytosterols (1–2 g/day)
may be considered for individuals with elevated TC and LDL-C
values in whom the total CV risk assessment does not justify the
use of cholesterol-lowering drugs.99
Other features of a healthy diet contributing to cardiovascular disease
prevention
The diet should be varied and rich in fruit and vegetables of differ-
ent types to obtain a sufficient amount and variety of antioxidants.
Table 10 Definition of central obesity
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At least two or three portions of fish per week are rec-
ommended to the general population for the prevention of
CVD, together with regular consumption of other food
sources of n-3 PUFAs (nuts, soy, and flaxseed oil); for secondary
prevention of CVD, the recommended amount of n-3 unsatu-
rated fat should be 1 g/day, which is not easy to derive exclu-
sively from natural food sources, and use of nutriceuticals and/
or pharmacological supplements may be considered. Salt
intake should be limited to ,5 g/day, not only by reducing the
amount of salt used for food seasoning but also by reducing
the consumption of foods preserved by the addition of salt;
this recommendation should be more stringent in people with
hypertension or MetS.5 Dietary recommendations to lower TC
and LDL-C are summarized in Table 11. Table 12 summarizes
lifestyle measures and healthy food choices for managing total
CV risk.
All individuals should be advised on lifestyles associated with a
lower CVD risk. High risk subjects, in particular those with dyslipi-
daemia, should receive specialist dietary advice, if feasible.
7. Drugs for treatment
of hypercholesterolaemia
Cholesterol levels are determined by multiple genetic factors as
well as environmental factors, primarily dietary habits. Hypercho-
lesterolaemia can also be secondary to other medical conditions.
Secondary dyslipidaemia can have different causes; the possibility
of secondary hypercholesterolaemia (Table 13) should be
Table 11 Dietary recommendations to lower TC and LDL-C
LDL-C ¼ LDL-cholesterol; TC ¼ total cholesterol.
Table 12 Summary of lifestyle measures and healthy
food choices for managing total cardiovascular risk
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considered before initiating therapy. As an example, mild hypothyr-
oidism is rather frequent and associated with cholesterol elevation;
the latter will be solved once thyroid function is normalized.
7.1 Statins
Mechanism of action
Statins reduce synthesis of cholesterol in the liver by competitively
inhibiting HMG-CoA reductase activity. The reduction in intra-
cellular cholesterol concentration induces low-density lipoprotein
receptor (LDLR) expression on the hepatocyte cell surface,
which results in increased extraction of LDL-C from the blood
and a decreased concentration of circulating LDL-C and other
apo B-containing lipoproteins including TG-rich particles.
Efficacy in clinical studies
Statins are among the most studied drugs in CV prevention, and
dealing with single studies is beyond the scope of the present
guidelines.
A number of large-scale clinical trials have demonstrated that
statins substantially reduce CV morbidity and mortality in both
primary and secondary prevention.15–17 Statins have also been
shown to slow the progression or even promote regression of
coronary atherosclerosis.18–40
Meta-analyses
In the CTT meta-analyses of individual participant data from .170
000 participants in 26 randomized trials of statins,15 a 10% pro-
portional reduction in all-cause mortality and 20% proportional
reduction in CAD death per 1.0 mmol/L (40 mg/dL) LDL-C
reduction is reported. The risk for major coronary events was
reduced by 23% and the risk for stroke was reduced by 17% per
mmol/L (40 mg/dL) LDL-C reduction. The proportional reductions
in major CV event rates per mmol/L (mg/dL) LDL-C reduction
were very similar in all of the subgroups examined. The benefits
were significant within the first year, but were greater in sub-
sequent years. There was no increased risk for any specific
non-CV cause of death, including cancer, in those receiving
statins. The excess risk of rhabdomyolysis with statins was small
and not significant. Information on episodes of increased liver
enzymes was not examined in this meta-analysis. Other
meta-analyses16,17,41 addressed the issue of primary prevention,
with results regarding efficacy and safety that are, in general, con-
sistent with the conclusions from the CTT.15 Regarding cost-
effectiveness and quality of life, caution is still needed in prescribing
statins for primary prevention among people at low total CV risk.41
At maximal recommended doses the different statins differ in
their LDL-C-lowering capacity.
Current available evidence suggests that the clinical benefit is
largely independent of the type of statin but depends on the
extent of LDL-C lowering; therefore, the type of statin used
should reflect the degree of LDL-C reduction that is required to
reach the target LDL-C in a given patient.15,100 More details on
this are provided in Addendum II to these guidelines.
The following scheme is proposed:
† Evaluate the total CV risk of the subject
† Involve the patient with decisions on CV risk management
† Identify the LDL-C target for that risk level
† Calculate the percentage reduction of LDL-C required to
achieve that goal
† Choose a statin that, on average, can provide this reduction
† Since the response to statin treatment is variable, up-titration to
reach target is mandatory
† If the statin cannot reach the goal, consider drug combinations.
Of course these will be only general criteria for the choice of drug.
The clinical conditions of the subjects, concomitant treatments,
and drug tolerability will play a major role in determining the
final choice of drug and dose.
Side effects and interactions
Statins differ in their absorption, bioavailability, plasma protein
binding, excretion and solubility. Lovastatin and simvastatin are
prodrugs, whereas the other available statins are administered in
their active form. Their absorption rate varies between 20 and
98%. Many statins undergo significant hepatic metabolism via cyto-
chrome P450 isoenzymes (CYPs), except pravastatin, rosuvastatin
and pitavastatin. These enzymes are expressed mainly in the liver
and gut wall.
Although statin treatment has beneficial effects in the prevention
of CVD, interindividual variation exists in response to statin
therapy, as well as in the incidence of adverse effects.
Muscle
Statins are generally well tolerated, and serious adverse events are
rare. Over 129 000 patients have been systematically studied in
controlled trials with blinded randomized assignment to statin vs.
placebo treatment groups.15 Factors such as advanced age, small
body size, female gender, renal and hepatic dysfunction, periopera-
tive periods, hypothyroidism, multisystem disease, and alcohol
abuse increase the likelihood of side effects with statins.
The most serious adverse effect associated with statin therapy is
myopathy, which may progress to rhabdomyolysis, and that, in
turn, can lead to renal failure and death. Creatine phosphokinase
(CK) elevation has become the primary marker for ongoing
muscle cell death and destruction. The myoglobin release from
these cells can directly damage the kidneys. An elevation of CK
is the best indicator, although not unequivocal, of statin-induced
Table 13 Examples of causes of secondary
hypercholesterolaemia
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myopathy. The common definition of a tolerable elevation has
been a rise of five times the upper limit of normal (ULN) of this
enzyme measured on two occasions. How statins injure skeletal
muscle is not clear. The incidence of myopathy is low (,1/1000
patients treated) and the excess risk in comparison with placebo-
treated patients has been ,1/10 000 patients treated in clinical
trials.
Myopathy is most likely to occur in persons with complex
medical problems and/or who are taking multiple medications, or
in elderly persons, especially women. Myalgia (without CK
elevation) occurs in 5–10% of patients in clinical practice. Patients
should be instructed on promptly reporting unexpected muscle
pain or weakness. However, patients complaining of myalgia
without elevated CK levels can continue the medication if their
symptoms are tolerable. If the symptoms are not tolerable or
are progressive, the drug should be stopped. The possibility of
re-challenge to verify the cause of the pain should be discussed
with the patient, as well as dose reduction, drug substitution,
and/or drug combinations. Potent drugs such as atorvastatin and
rosuvastatin can often be used on intermittent days to reduce
side effects.
Liver
The activity of alanine aminotransferase (ALT) and aspartate ami-
notransaminase in blood plasma is commonly used by clinicians
to assess hepatocellular damage. These measures have been mon-
itored in all significant statin trials. Elevated hepatic transaminases
occur in 0.5–2.0% of statin-treated patients and are dose depen-
dent. The common definition of a meaningful elevation has been
a rise of three times the ULN of these enzymes on two occasions,
usually measured within a short interval of days to a few weeks.
Whether transaminase elevation with statins constitutes true hepa-
totoxicity has not been determined. Progression to liver failure is
exceedingly rare. Reversal of transaminase elevation is frequently
noted with reduction of dose; thus, a patient who develops
increased transaminase levels should be monitored with a
second liver function evaluation to confirm the finding and be fol-
lowed thereafter with frequent liver function tests until the
abnormality returns to normal. Should an increase in transaminase
levels of .3 times the ULN or greater persist, therapy should be
discontinued.
Type 2 diabetes
The recent finding that the incidence of diabetes may increase with
statins should not discourage institution of treatment; the absolute
reduction in the risk of CVD in high risk patients outweighs the
possible adverse effects of a very small increase in the incidence
of diabetes.101
Other effects
Results from observational studies have suggested other unintended
benefits and adverse effects related to statin therapy102,103 such as
multiple sclerosis, Alzheimer disease, and respiratory diseases.
These results need confirmation, preferably in RCTs, and emphasize
the need for long-term pharmaco-surveillance.
Interactions
A number of important drug interactions with statins have been
described that may increase the risk of side effects. Inhibitors
and inducers of enzymatic pathways involved in statin metabolism
are summarized in a table in Addendum III of these guidelines. All
currently available statins, except pravastatin, rosuvastatin, and
pitavastatin, undergo major hepatic metabolism via the CYPs.
These isoenzymes are mainly expressed in liver and intestine. Pra-
vastatin does not undergo metabolism through the CYP system
but is metabolized by sulfation and conjugation. CYP3A isoen-
zymes are the most abundant, but other isoenzymes such as
CYP3A4, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 are also
involved in the metabolism of statins. Thus, other pharmacological
substrates of these CYPs may interfere with statin metabolism.
Conversely statin therapy may interfere with the catabolism of
other drugs that are metabolized by the same enzymatic system.
Combinations of statins with fibrates may enhance the risk for
myopathy. This risk is highest for gemfibrozil, and the association
of gemfibrozil with statins should be avoided. The increased risk
for myopathy when combining statins with other fibrates such as
fenofibrate, bezafibrate, or ciprofibrate seems to be small.104,105
The increased risk for myopathy with nicotinic acid has been
debated, but in recent reviews no increased risk of myopathy
was found with this agent.106,107
7.2 Bile acid sequestrants
Mechanism of action
Bile acids are synthesized in the liver from cholesterol. The bile
acids are released into the intestinal lumen, but most of the bile
acid is returned to the liver from the terminal ileum via active
absorption. The two older bile acid sequestrants, cholestyramine
and colestipol, are both bile acid-binding exchange resins. Recently
colesevelam has been introduced into the market. The bile acid
sequestrants are not systemically absorbed or altered by digestive
enzymes. Therefore, the beneficial clinical effects are indirect. By
binding the bile acids, the drugs prevent the entry of bile acid
into the blood and thereby remove a large portion of the bile
acids from the enterohepatic circulation. The liver, depleted of
bile, synthesizes more from hepatic stores of cholesterol. The
decrease in bile acid returned to the liver leads to up-regulation
of key enzymes responsible for bile acid synthesis from cholesterol,
particularly CYP7A1. The increase in cholesterol catabolism to bile
acids results in a compensatory increase in hepatic LDLR activity,
clearing LDL-C from the circulation and thus reducing LDL-C
levels. These agents also reduce glucose levels in hyperglycaemic
patients; however, the mechanism behind this reduction is not
completely clear.
Efficacy in clinical studies
At the top dose of 24 g of cholestyramine, 20 g of colestipol, or
4.5 g of cholestagel, a reduction in LDL-C of 18–25% has been
observed. No major effect on HDL-C has been reported, while
TG may increase in some predisposed patients.
In clinical trials, bile acid sequestrants have contributed greatly
to the original demonstration of the efficacy of LDL-C lowering
in reducing CV events in hypercholesterolaemic subjects, with a
benefit proportional to the degree of LDL-C lowering.108
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Side effects and interactions
Gastrointestinal adverse effects (most commonly flatulence, con-
stipation, dyspepsia and nausea) are often present with these
drugs even at low doses, which limit their practical use. These
side effects can be attenuated by beginning treatment at low
doses and ingesting ample fluid with the drug. The dose should
be increased gradually. Reduced absorption of fat-soluble vitamins
has been reported. Furthermore, these drugs may increase TG in
certain patients.
Bile acid sequestrants have important drug interactions with
many commonly prescribed drugs and should therefore be admi-
nistered either 4 h before or 1 h after other drugs. Colesevelam
represents a newer formulation of the bile acid sequestrant,
which may be better tolerated than cholestyramine. The drug
reduces LDL-C and also improves glycated haemoglobin (HbA1C)
in patients with type 2 diabetes.109,110 Colesevelam has fewer
interactions with other drugs and can be taken together with
statins. For other drugs, however, the same general rules for
administration as for other sequestrants should be applied.
7.3 Cholesterol absorption inhibitors
Mechanism of action
Ezetimibe is the first lipid-lowering drug that inhibits intestinal
uptake of dietary and biliary cholesterol without affecting the
absorption of fat-soluble nutrients. By inhibiting cholesterol
absorption at the level of the brush border of the intestine
(most probably by interacting with the NPC1L1 protein), ezeti-
mibe reduces the amount of lipoprotein cholesterol circulated to
the liver. In response to reduced cholesterol delivery, the liver
reacts by up-regulating LDLR, which in turn leads to increased
clearance of LDL from the blood.
Efficacy in clinical studies
In clinical studies ezetimibe in monotherapy reduces LDL-C in
hypercholesterolaemic patients by 15–22%. Combined therapy
with ezetimibe and a statin provides an incremental reduction in
LDL-C levels of 15–20%. The efficacy of ezetimibe in association
with simvastatin has been addressed in subjects with aortic stenosis
in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study38
and in patients with CKD in the Study of Heart and Renal Protec-
tion (SHARP) (see Sections 7.5.2 and 10.9). In the SHARP study a
reduction of 17% in CV events was demonstrated in the simvasta-
tin–ezetimibe arm vs. placebo.111
Ezetimibe can be used as second-line therapy in association with
statins when the therapeutic target is not achieved at maximal
tolerated statin dose or in patients intolerant of statins or with
contraindications to these drugs.
Side effects and interactions
Ezetimibe is rapidly absorbed and extensively metabolized to
the pharmacologically active ezetimibe glucuronide. The rec-
ommended dose of ezetimibe of 10 mg/day can be administered
in the morning or evening without regard to food intake. There
are no clinically significant effects of age, sex, or race on ezetimibe
pharmacokinetics, and no dosage adjustment is necessary in
patients with mild hepatic impairment or mild to severe renal insuf-
ficiency. Ezetimibe can be co-administered with any dose of any
statin. No major side effects have been reported; the most fre-
quent side effects are moderate elevations of liver enzymes, and
muscle pain.
7.4 Nicotinic acid
Nicotinic acid has broad lipid-modulating action, raising HDL-C in a
dose-dependent manner by 25%, and reducing both LDL-C by
15–18% and TG by 20–40% at the 2 g/day dose. Nicotinic acid
is unique in lowering Lp(a) levels by up to 30% at this dose. It is
therefore primarily used in subjects with low HDL-C levels as
typical of mixed hyperlipidaemia, HTG, or in FCH, but may also
be used in subjects with insulin resistance (type 2 diabetes and
MetS). Nicotinic acid may be used in combination with statins
(see also Sections 8.3 and 8.5.2).112
7.5 Drug combinations
Although the target levels of LDL-C are reached with monother-
apy in many patients, a proportion of high risk subjects or patients
with very high LDL-C levels need additional treatment. There are
also patients who are statin intolerant or are not able to tolerate
higher statin doses. In these cases combination therapy should
be considered.113
7.5.1 Statins and bile acid sequestrants
Combination of a statin and cholestyramine, colestipol, or colese-
velam could be useful in achieving LDL-C goals. On average the
addition of a bile acid sequestrant to a statin reduces LDL-C
further by 10–20%. However, there are no published clinical
outcome trials with either conventional bile acid sequestrants or
colesevelam in combination with other drugs. The combination
has been found to reduce atherosclerosis, as evaluated by coron-
ary angiography.113–115
7.5.2 Statins and cholesterol absorption inhibitors
Combining ezetimibe with a statin reduces LDL-C by an additional
15–20%.116 The results of the SEAS study in patients with asymp-
tomatic aortic stenosis showed that ezetimibe and simvastatin
applied concomitantly reduce the incidence of ischaemic CVD
events (up to 46% in the patients with less severe aortic stenosis)
but not events related to aortic valve stenosis.38 Recently the data
of the SHARP trial were presented with positive results in CKD
patients (see Section 10.9).111
7.5.3 Other combinations
In high risk patients such as those with FH, or in cases of
statin intolerance, other combinations may be considered.
Co-administration of ezetimibe and bile acid sequestrants (colese-
velam, colestipol, or cholestyramine) resulted in an additional
reduction of LDL-C levels without any additional adverse effects
when compared with the stable bile acid sequestrant regimen
alone. Adding ezetimibe to nicotinic acid further reduces LDL-C
and does not affect nicotinic acid-induced HDL-C increase. Also
triple therapy (bile acid sequestrant, statin, and ezetimibe or
nicotinic acid) will further reduce LDL-C. Clinical outcome
studies with these combinations have not been performed.
Functional food containing phytosterols as well as plant sterol-
containing tablets additionally reduce LDL-C levels by up to
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5–10% in patients taking a stable dose of a statin, and this com-
bination is also well tolerated and safe67 (see also Section 6.4)
However, it is still not known whether this could reduce the risk
of CVD since no trials with plant sterols in combination with
other lipid-lowering drugs are available for CVD outcomes.
7.6 Low-density lipoprotein apheresis
Rare patients with severe hyperlipidaemias, especially homozygous
and severe heterozygous FH, require specialist evaluation and con-
sideration of the need for LDL apheresis. By this expensive but
effective technique, LDL and Lp(a) are removed from plasma
during extracorporeal circulation weekly or every other week.
Clearly this is a procedure that is only performed in highly
specialized centres.
7.7 Future perspectives
Recently a number of promising new drugs have reached phase III
in clinical trials and have been reported to lower LDL-C effectively
in severe hypercholesterolaemias, including microsomal transfer
protein (MTP) inhibitors,117 thyroid hormone mimetics with liver
selectivity,118 and oligonucleotides such as mipomersen that
specifically suppress apo B.119 All these approaches may further
help in achieving therapeutic targets in people with severe or
familial forms of hyperlipidaemia, especially FH patients.
Recommendations for the pharmacological treatment of
hypercholesterolaemia are shown in Table 14.
8. Drugs for treatment
of hypertriglyceridaemia
Triglycerides and cardiovascular disease risk
Although the role of TG as a risk factor for CVD has been strongly
debated, recent data strongly favour the role of TG-rich lipoproteins
as a risk factor for CVD.121 Recent large prospective studies
reported that non-fasting TG predict CHD risk more strongly than
fasting TG.12,45 Whether the impact of high TG levels on CVD risk
is explained by the burden of remnant particles, small dense LDLpar-
ticles or associated low HDL remains unsettled.121 Recently,
non-HDL-C has turned out to be a good surrogate marker of TG
and remnants.42 The burden of HTG as a CVD risk factor is high-
lighted by the fact that about one-third of adult individuals have TG




Action to prevent acute pancreatitis
One of the major clinical risks of dramatically elevated TG is acute
pancreatitis. The risk of pancreatitis is clinically significant if
TG exceed 10 mmol/L (more than 880 mg/dL) and actions to
prevent acute pancreatitis are mandatory. Notably HTG is the
cause of 10% of all cases with pancreatitis, and patients can
develop pancreatitis even when their TG concentration is
between 5 and 10 mmol/L (440–880 mg/dL).
Admit the patient to the hospital if symptomatic or secure a
careful and close follow-up of the patient’s TG values. Restriction
of calories and fat content (10–15% recommended) of the diet
and alcohol abstinence are obligatory. Initiate fibrate therapy
(fenofibrate) with n-3 fatty acids (2–4 g/day) as adjunct therapy
or nicotinic acid. In patients with diabetes, initiate insulin therapy
to achieve a good glycaemic control. In general a sharp decrease
of TG values is seen within 2–5 days. In the acute setting apheresis
is able to lower TG levels rapidly.123
Strategies to control plasma triglycerides
Even though the role of TG as a risk factor of CVD remains uncer-
tain, a level of fasting TG ,1.7 mmol/L or less than 150 mg/dL is
desirable.
The first step is to consider possible causes of HTG and to
evaluate the total CV risk. The primary goal will be to achieve
the LDL-C target based on the total CV risk level. As compared
with the overwhelming evidence for the benefits of LDL-C
reduction, the evidence on the benefits of lowering elevated TG
levels is still modest.
Lifestyle management
The influence of lifestyle management on TG levels is well docu-
mented. Weight reduction together with a regular physical activity
programme of moderate intensity can reduce TG between 20 and
30%, and should be mandatory for all patients with obesity, MetS,
or type 2 diabetes.
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Although the CVD risk is increased if fasting TG are .1.7 mmol/L
(more than 150 mg/dL),121 the use of drugs to lower TG should
only be considered in subjects with TG .2.3 mmol/L (more than
200 mg/dL) who cannot lower them by lifestyle measures, and if
the subject is at high total CV risk.
The available pharmacological interventions include statins,
fibrates, nicotinic acid, and n-3 PUFAs. As statins have significant
effects on mortality as well as most CVD outcome parameters,
these drugs are the first choice to reduce both total CVD risk and
moderately elevated TG levels. More potent statins (atorvastatin,
rosuvastatin, and pitavastatin) demonstrate a robust lowering of
TG levels, especially at high doses and in patients with elevated TG.
8.2 Fibrates
Mechanism of action
Fibrates are agonists of peroxisome proliferator-activated
receptor-a (PPAR-a), acting via transcription factors regulating
various steps in lipid and lipoprotein metabolism. By interacting
with PPAR-a, fibrates recruit different cofactors and regulate
gene expression. As a consequence, fibrates have good efficacy
in lowering fasting TG levels as well as post-prandial TG and
triglyceride-rich lipoprotein (TRL) remnant particles. The
HDL-C-raising effects of fibrates are modest.112
Efficacy in clinical trials
The clinical benefits of fibrates in monotherapy are primarily
illustrated by four prospective, randomized, placebo-controlled,
clinical trials: Helsinki Heart Study (HHS), Veterans Affairs High-
density lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarc-
tion Prevention study (BIP), and FIELD.124–127 The data from these
trials have shown consistent decreases in the rates of non-fatal MI
(although often as a result of post-hoc analyses), the effect being
most robust in subjects with elevated TG/low HDL-C levels.
However, the data on other outcome parameters have remained
equivocal. Thus, the overall efficacy of fibrates on CVD outcomes
is much less robust than that of statins. Recent meta-analyses
reported that fibrate therapy reduced major CVD events by 13%
[95% confidence interval (CI) 7–19], the benefits being most
robust in patients with elevated TG levels (.2.3 mmol/L or
more than 200 mg/dl).52
Side effects and interactions
Fibrates are generally well tolerated with mild side effects, gastro-
intestinal disturbance being reported in 5% of the patients and
skin rashes in 2%.128 In general, myopathy, liver enzyme elevations,
and cholelithiasis represent the most well known safety issues
associated with fibrate therapy.128 In the FIELD study, small but sig-
nificant increases in the incidence of pancreatitis (0.8% vs. 0.5%)
and of pulmonary embolism (1.1% vs. 0.7%), and a non-significant
trend toward an increase in deep vein thrombosis (1.4% vs. 1.0%)
were seen in those taking fenofibrate compared with placebo; this
is in line with data from other fibrate studies.127
Elevations of both CK (.5 times above the ULN) and ALT (.3
times above the ULN) were reported more frequently for patients
on fenofibrate than on placebo, but the incidence of these
abnormalities remained ,1% in both treatment groups.
In the FIELD study, one case of rhabdomyolysis was reported in
the placebo group and three cases in the fenofibrate group.127 The
risk of myopathy has been reported to be 5.5-fold greater with
fibrate use as a monotherapy compared with statin use.128 The
risk of myopathy is greater in patients with CKD, and it varies
with different fibrates and statins used in combination. This is
explained by the pharmacological interaction between different
fibrates and glucoronidation of statins. Gemfibrozil inhibits the
metabolism of statins via the glucuronidation pathway that leads
to highly increased plasma concentrations of statins. As fenofibrate
does not share the same pharmacokinetic pathways as gemfibrozil,
the risk of myopathy is much less with the combination therapy.128
As a class, fibrates have been reported to raise both serum crea-
tinine and homocysteine in both short-term and long-term studies,
but the effect seems to be fibrate specific. Whether the increase of
serum creatinine reflects kidney dysfunction or not is a matter of
ongoing debate, but clearly an annual monitoring of creatinine
levels particularly in people with type 2 diabetes is necessary.
The increase in homocysteine by fibrates has been considered
to be relatively innocent with respect to CVD risk. However,
the fibrate-induced increase in homocysteine may blunt the
increases in both HDL-C and apo A1, and this may contribute
to the smaller than estimated benefits of fenofibrate in the
outcome parameters.129 High homocysteine also promotes throm-
bosis, and this may explain the increased trend to deep vein
Table 15 Possible causes of HTG
HTG ¼ hypertriglyceridaemia; SLE ¼ systemic lupus erythematosus, TG ¼
triglyceride.
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Nicotinic acid has been reported to decrease fatty acid influx to
the liver and the secretion of VLDL by the liver; this effect
appears to be mediated in part by the effects on hormone-sensitive
lipase in the adipose tissue. Nicotinic acid has key action sites in
both liver and adipose tissue. In the liver nicotinic acid is reported
to inhibit diacylglycerol acyltransferase-2 (DGAT-2) that results in
the decreased secretion of VLDL particles from the liver, which is
also reflected in reductions of both IDL and LDL particles.130
Nicotinic acid raises HDL-C and apo A1 primarily by stimulating
apo A1 production in the liver.130 The effects of nicotinic acid
on lipolysis and fatty acid mobilization in adipocytes are well
established.
Efficacy in clinical trials
Nicotinic acid has multiple beneficial effects on serum lipids and lipo-
protein.130 Nicotinic acid reduces effectively not only TG but also
LDL-C, reflecting its effect on all apo B-containing proteins. Nicotinic
acid increases apoA1-containing lipoproteins, reflected in increasesof
HDL-C and apo A1. Nicotinic acid is currently used mostly as an
extended release (ER) form. At the daily dose of 2 g it reduces TG
by 20–40% and LDL-C by 15–18%, and increases HDL-C by
15–35%.130 Currently available outcome data for nicotinic acid
from randomized clinical trials are still limited.120,131 The favourable
effect on angiographic measures has been reported in the Familial
Atherosclerosis Treatment Study (FATS) and in the
HDL-Atherosclerosis Treatment Study (HATS).132 In statin-treated
patients with low HDL-C, high dose, modified release nicotinic acid,
compared with placebo, significantly reduced carotid wall area, quan-
tified by magnetic resonance imaging after 1 year.133 Two large
ongoing trials (the AIM-HIGH and the HPS2-THRIVE) using, respect-
ively, ERnicotinic acid vs. placebo in addition to simvastatin and ERnic-
otinic acid/laropiprant vs. placebo in patients treated with simvastatin
(plus, if indicated, ezetimibe)will provide additional data on the effects
of nicotinic acid on CVD risk in combination with statin therapy.
In the Arterial Biology for the Investigation of the Treatment
Effects of Reducing Cholesterol 6: HDL and LDL Treatment Strat-
egies in Atherosclerosis (ARBITER-6 HALTS) trial with 315
patients, ER nicotinic acid was shown to be more effective than
ezetimibe at reducing CIMT on a background of statin therapy in
patients with LDL-C ,2.5 mmol/L (less than 100 mg/dL).134
Side effects and interactions
In clinical practice, skin reactions (flushing) are the most frequent
and troublesome side effect of nicotinic acid and its derivatives,
often preventing titration of the dose to maximal efficacy, even
using aspirin as a modulator of flushing. Other side effects of nic-
otinic acid include hyperuricaemia, liver toxicity, and acanthosis
nigricans. Recently, specific receptors [G protein-coupled receptor
(GPR) 109A and GPR 109B] for nicotinic acid were discovered in
adipocytes. Interestingly, the presence of these receptor in macro-
phages in the skin seems to be the link to the most robust side
effect of nicotinic acid, the flushing phenomenon associated with
itching and tingling. The mediator is prostaglandin D2 released
from arachidonic acid. Laropiprant is a selective antagonist of pros-
taglandin D2 action at the receptor level. A nicotinic acid/laropipr-
ant combination has been approved by the European Medicines
Agency (EMEA) for clinical use. A recent survey revealed that
,15% of new users of ER nicotinic acid were still using the drug
after 1 year. The recently introduced association with laropiprant
might help in reducing the incidence of this side effect. Elevation
of liver enzymes in users of ER nicotinic acid is less common
(,1%) than with previous nicotinic acid compounds. The issue
that nicotinic acid may interfere with glycaemic control by increas-
ing blood glucose levels is of concern in treating people with dia-
betes. In clinical practice, the titration of glucose-lowering
medication can be utilized to overcome these unfavourable effects.
8.4 n-3 fatty acids
Mechanism of action
n-3 fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA)] are components of fish oil and the Mediterranean
diet, and have been used to lower TG. n-3 fatty acids at pharmaco-
logical doses (.2 g/day) affect serum lipids and lipoproteins, in
particular VLDL concentration. The underlying mechanism is
poorly understood, although it may be related, at least in part,
to their ability to interact with PPARs and to a decreased secretion
of apo B.
Efficacy in clinical trials
Fishoil reduces TGby30%, but the effects onother lipoproteins are
trivial in their magnitude. More detailed data on clinical outcomes are
needed to justify the use of prescription n-3 fatty acids.135 The rec-
ommended doses of total EPA and DHA to lower TG have varied
between 2 and 4 g/day. The Food and Drug Administration (FDA)
has approved the use of n-3 fatty acids (prescription products) as an
adjunct to the diet if TG exceed 5.6 mmol/L (496 mg/dL). The
average reduction of TG is 30% and the benefit seems to be dose
dependent, being 45% in subjects with baseline TG values
.5.6 mmol/L (496 mg/dL).135 Although a recent Japanese study in
patients with hypercholesterolaemia reported a 19% reduction in
CVD outcome,136 the data remain inconclusive137 and their clinical
efficacy appears to be related to non-lipid effects.138
Safety and interactions
The administration of n-3 fatty acids appears to be safe and devoid
of clinically significant interactions. However, the antithrombotic
effects may increase the propensity to bleed, especially when
given in addition to aspirin/clopidogrel.
8.5 Drug combinations
8.5.1 Statins and fibrates
Clinical trials have shown that the combination of a statin and a
fibrate, particularly fenofibrate, bezafibrate, or ciprofibrate,
results in a significantly stronger reduction in LDL-C and TG as
well as a greater elevation of HDL-C than monotherapy with
either.139 Since both fibrate and statin monotherapy are associated
with an increased risk of myopathy, the risk could be increased
when these drugs are taken together, particularly if the doses of
statin are very high. However, the risk is 15-fold higher if
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gemfibrozil is used than if fenofibrate is co-administered with any
of five commonly used statins.140 Therefore, it seems that this is
most probably not a class effect of fibrates but rather a problem
only with gemfibrozil. Based upon data from many trials, fibrates,
particularly fenofibrate due to its lower myopathic potential, can
be prescribed concomitantly with statins to improve achievement
of lipid goals in patients with atherogenic combined dyslipidaemia,
especially patients with MetS and/or diabetes. Patients should still
be instructed about warning symptoms (myalgia), but since such
adverse effects are very rare they should not be the reason to
deny the combined treatment to patients who really need it.
This combination should be prescribed with caution to patients
who are also receiving other drugs metabolized through cyto-
chrome P450. Fibrates should preferably be taken in the morning
and statins in the evening to minimize peak dose concentrations.
Avoidance of adding gemfibrozil to a statin regimen is advised.
In the Action to Control Cardiovascular Risk in Diabetes
(ACCORD) trial,141 in patients with type 2 diabetes the combi-
nation therapy of fenofibrate with simvastatin did not reduce the
rates of CVD as compared with simvastatin alone when all the
patients were analysed together. However, patients who had
both TG levels in the higher third (≥2.3 mmol/L or ≥204 mg/
dL) and an HDL-C level below the lower third (≤0.88 mmol/L
or ≤34 mg/dL)—representing 17% of all participants—appeared
to benefit from the combination therapy. These results are
similar to those from post-hoc analyses performed in the
HHS,124 BIP,126 and FIELD studies.127 Therefore, these results
from ACCORD and from previous trials suggest that the addition
of fenofibrate to a statin may benefit certain patients with type 2
diabetes with a high TG/low HDL-C dyslipidaemic pattern.
8.5.2 Statins and nicotinic acid
The combination of ER nicotinic acid with moderate doses of a statin
provides a significantly better increase in HDL-C and decrease in TG
than either a high dose of a statin or the combination of a statin and
ezetimibe.142 Patients taking concomitant statin therapy, mostly sim-
vastatin or atorvastatin, with nicotinic acid report a similar incidence
of all-cause adverse events, and the incidence of flushing is similar in
patients with and without statin treatment. Triple combination
therapy with nicotinic acid, simvastatin, and ezetimibe showed a
stronger lowering of LDL-C and a stronger increase in HDL-C than
with either drug alone or with statin/ezetimibe treatment.143
Several studies have shown that the combination of nicotinic acid
and colestipol causes a higher frequency of absolute regression of
atherosclerotic lesions than colestipol alone.144 The HATS study
showed not only a small regression of angiographically measured cor-
onary plaques due to combined nicotinic acid and statin treatment as
compared with progression observed on placebo, but also 90% lower
risk of CV events, although in a very small number of patients.145
8.5.3 Statins and n-3 fatty acids
Treatment with a combination of 4 g/day n-3 fatty acids and simvas-
tatin caused a stronger reduction of TG concentrations and a small
but significant increase in HDL-C when compared with statin
alone.146 Adding n-3 fatty acids to pravastatin and fenofibrate in
a triple combination further decreased TG concentrations and
homocysteine as well in patients with diabetic dyslipidaemia. No
significant interactions of any drug with n-3 fatty acids have been
described. In one study EPA combined with low dose pravastatin
or simvastatin compared with statin therapy alone reduced
major coronary events without altering rates of sudden cardiac
death.136 However, since these effects were achieved without
any significant changes in TC, LDL-C, or HDL-C, and just a small
decrease in TG, EPA may lower CAD risk by mechanisms other
than LDL-C lowering. In a subgroup analysis, such a combined
treatment also reduced the incidence of CAD events in high risk
patients with MetS and therefore a high TG/low HDL-C dyslipidae-
mic pattern.147
Recommendations for the drug treatment of HTG are shown in
Table 16.
9. Drugs affecting high-density
lipoprotein
High-density lipoprotein and cardiovascular disease risk
Low levels of HDL-C constitute a strong, independent, and inverse
predictor of the risk of premature development of atherosclerosis
and CVD.11 Moreover, the decrease in CV risk relative to HDL-C
levels is especially dramatic over the range of HDL-C from 0.65
to 1.17 mmol/L (25–45 mg/dL).148 Elevation of ≥7.5% in HDL-C,
together with a reduction in LDL-C to a target of ,2.0 mmol/L
(less than 80 mg/dL), represented the minimum requirement





dEvidence for additional lipid-lowering, compared with monotherapy.
eThe evidence for prevention of CVD using combination therapy is in general
limited.
CVD ¼ cardiovascular disease; HTG ¼ hypertriglyceridaemia.
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for plaque regression in a meta-analysis of four intervention trials,
which involved use of intravascular ultrasound to evaluate changes
in coronary atheroma volume.149
Low plasma concentrations of HDL-C are frequently a charac-
teristic of type 2 diabetes as well as mixed or combined dyslipidae-
mia, renal and hepatic insufficiency states, and autoimmune
diseases. In addition to low HDL-C, these disease states feature
a moderate or marked degree of HTG. The intravascular metab-
olism of TG-rich lipoproteins (principally VLDL) is intimately
linked to that of HDL. Drug-induced raising of HDL-C may lead
to beneficial reduction in the cholesterol content of both VLDL
and LDL; the magnitude of reduction in VLDL-cholesterol
(VLDL-C) and LDL-C under these circumstances tends to differ
markedly as a function of the specific mechanism of action of the
pharmacological agent concerned, as well as the dose employed
and the baseline lipid phenotype. Furthermore, the percentage
increase in HDL-C following treatment tends to be greater in sub-
jects with the lowest baseline levels.150
The available options for elevating low HDL-C levels are rela-
tively few. While HDL-C levels may be increased by up to
10% by implementing therapeutic lifestyle changes, including
weight reduction, exercise, smoking cessation, and moderate
alcohol consumption, many patients will also require pharmaco-
logical intervention if target levels should be set. However, there
is until now no clear direct evidence that raising HDL-C really
results in CVD prevention. This is being tested in the Dalcetrapib
Outcomes (dal-OUTCOMES), HPS2-THRIVE (nicotinic acid plus
statin), AIM-HIGH (nicotinic acid on background statin), and Ran-
domized Evaluation of the Effects of Anacetrapib Through Lipid-
modification (REVEAL) trials.
9.1 Statins
Statins produce modest elevations in HDL-C. In the recent
meta-analysis146 of several intervention studies in dyslipidaemic
patients, elevations in HDL-C varied with dose among the respect-
ive statins; such elevations were typically limited to the range of
5–10%.
As a result of the marked reductions in atherogenic apo
B-containing lipoproteins by statins, it is difficult to assess the
extent to which the smaller effect on HDL-C levels might contrib-
ute to the overall observed reductions in CV risk consistently seen
in statin intervention trials. Despite such an effect, however, the
elevated CV risk associated specifically with low HDL-C levels
was only partially corrected by statin treatment in the Treatment
to New Targets (TNT) trial.151
9.2 Fibrates
As a class, fibrates differ in their potential to modulate the athero-
genic lipid profile by concomitantly lowering TG levels (up to 50%)
and by raising those of HDL-C (up to 10–15% in short-term
studies). However, the HDL-raising effect has been markedly less
(,5%) in the long-term intervention trials in people with type 2
diabetes127,141; such differences appear to reflect distinctions in
their relative binding affinities for PPARs and notably for
PPAR-a.152
9.3 Nicotinic acid
Nicotinic acid appears to increase HDL-C by partially reducing
HDL catabolism and mainly by increasing apo A1 synthesis by
the liver. The latter effect is regarded as the most relevant for
the HDL functions.112
Efficacy in clinical trials and side effects and drug interactions
have been described in Section 8.3.
9.4 Cholesteryl ester transfer protein
inhibitors
To date, the most efficacious pharmacological approach to
elevation of low HDL-C levels has involved direct inhibition of
cholesteryl ester transfer protein (CETP) by small molecule inhibi-
tors, which may induce an increase in HDL-C by ≥100% on a
dose-dependent basis. Among three CETP inhibitors developed
originally (torcetrapib, dalcetrapib, and anacetrapib), torcetrapib
was withdrawn following an excess of mortality in the torcetrapib
arm of the Investigation of Lipid Levels Management to Understand
its Impact in Atherosclerotic Events (ILLUMINATE) trial.153
Retrospectively, it appears that the deleterious effects of torce-
trapib arose primarily from off-target toxicity related to activation
of the renin–angiotensin–aldosterone system (RAAS). Develop-
ment of dalcetrapib and anacetrapib is ongoing, and the
Dal-OUTCOMES trial has recently been launched; this trial is a
safety and outcomes trial of dalcetrapib in ACS patients. A phase
III trial (REVEAL) with anacetrapib will start in 2011.
9.5 Future perspectives
Major developments in the search for efficacious agents to raise
HDL-C and apo A1 with concomitant benefit on atherosclerosis
and CV events are on the horizon. Among them, major interest
is focused on apo A1 mimetic peptides which are not only active
in cellular cholesterol efflux, but may also exert anti-inflammatory
effects.





HDL-C ¼ high-density lipoprotein-cholesterol.
ESC/EAS Guidelines 1797
 at Bibliotheque Fac de M






Table 17 lists the recommendations when considering drug
treatment of low HDL-C.
Table 18 summarizes the efficacy of drug combinations in the
management of mixed dyslipidaemias.
10. Management of dyslipidaemias
in different clinical settings
10.1 Familial dyslipidaemias
Plasma lipid levels are to a very large extent determined by genetic
factors. In its more extreme forms this is manifested as familial
hyperlipidaemia. A number of monogenic lipid disorders have
been identified, and among those FH is most common and strongly
related to CVD. Most commonly the pattern of inheritance does
not suggest that there is a major single gene disorder (monogenic)
causing the abnormality, but rather that it stems from inheriting
more than one lipoprotein gene variant which, on its own, might
have relatively little effect, but in combination with another or
others has a greater influence on TC, TG, or HDL-C. This
pattern of inheritance is called polygenic. It is very common to
find that high LDL-C, high TG, or low HDL-C affect several
family members.
10.1.1 Familial combined hyperlipidaemia
FCH is a highly prevalent genetic dyslipidaemia (1:100) and an
important cause of premature CAD. FCH is characterized by elev-
ated levels of LDL-C, TG, or both. The phenotype varies even
among members from the same family. FCH shares considerable
phenotype overlap with type 2 diabetes and MetS. FCH is a
complex disease and the phenotype is determined by interaction
of multiple susceptibility genes and the environment. The pheno-
type even within a family shows high inter- and intraperson varia-
bility based on lipid values (TG, LDL-C, HDL-C, and apo B).
Therefore, the diagnosis is commonly missed in clinical practice;
the combination of apo B .120 mg/dL + TG .1.5 mmol/L
(133 mg/dL) with a family history of premature CVD can be
used to identify subjects who most probably have FCH.154 Cur-
rently research is ongoing to define genetic markers; hopefully
this approach will facilitate diagnosis of this frequent genetic
dyslipidaemia.
The concept of FCH is also valuable clinically in assessing CV
risk. It emphasizes both the importance of considering family
history in deciding how rigorously to treat dyslipidaemia, and
that raised LDL-C levels are riskier when HTG is also present.
Statin treatment has been shown to decrease CV risk by the
same relative amount in people with HTG as in those without.
Because the absolute risk is often greater in those with HTG,
they may therefore benefit greatly from hypocholesterolaemic
therapy.
10.1.2 Familial hypercholesterolaemia
Heterozygous familial hypercholesterolaemia (HeFH) affects 1 in
500 people of European descent. It is a dominantly inherited con-
dition and is generally fully penetrant. Affected individuals typically
have LDL-C levels which are about double that of their unaffected
siblings. This is because the proportion of circulating LDL they can
catabolize is decreased. Most commonly this is due to a mutation
of the LDLR. Occasionally HeFH syndrome can be caused by
mutations of genes other than the LDLR. One of these is propro-
tein convertase subtilisin/Kexin 9 (PCSK9) and the other apo B.
Clinically, HeFH can be recognized by particularly high levels of
LDL-C in the range of 5–10 mmol/L (200–400 mg/dL) in adult-
hood. Generally TG levels are normal, but can occasionally be
raised in adults, particularly if they are obese. The typical HeFH
patient may not in appearance conform at all to the clinician’s
concept of a coronary-prone individual. CVD risk estimation
methods based on multivariate risk equations alone are not suffi-
cient to estimate the risk of individuals with FH. Furthermore,
the risk related to HeFH can be substantially ameliorated by
early treatment. Untreated, the majority of affected men and
women will have symptomatic coronary disease by 60 years and
half of the men and 15% of the women will have died. On the
other hand, patients who start attending a lipid clinic before they
develop clinical CAD may enjoy a normal life expectancy if well
managed.155 An extensive review of the literature and treatment
of FH is found in a report of the National Institute for Health
and Clinical Excellence (NICE).156
Strategy for heterozygous familial hypercholesterolaemia case finding
Family history. Often attention is drawn to the possibility that HeFH
may be running in a family because of the occurrence of a coronary
event in a family member early in life. Occasionally, however,
because, even in HeFH, women have a lower risk of CAD, a
male patient may inherit HeFH from his mother and himself have
a CAD event before she has any symptoms of CAD. A family
history of early-onset CVD is also, of course, all too common in
countries with a high prevalence of CVD for reasons other than
HeFH. Reliance on family history can thus be misleading in the
diagnosis of HeFH. However, raised TC in the presence of CAD
in a male before 50 or a female before 60 years of age should
always prompt a family screening for other cases of raised TC.
Tendon xanthomata. Corneal arcus or xanthelasmata in a young
person should always prompt the measurement of TC, but
Table 18 Summary of the efficacy of drug
combinations for the management of mixed
dyslipidaemias
HDL-C ¼ high-density lipoprotein-cholesterol; LDL-C ¼ low-density
lipoprotein-cholesterol; TG ¼ triglyceride.
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neither is specific for HeFH. The presence of tendon xanthomata
is, however, virtually diagnostic of HeFH. Other causes are homo-
zygous FH (HoFH), cerebrotendinous xanthomatosis, and sitoster-
olaemia, all of which are exceedingly rare. The most common sites
to find tendon xanthomata are in the extensor tendons on the
dorsum of the hand and in the Achilles tendon. The MedPed and
WHO criteria have been used extensively to identify the HeFH
phenotype (Table 19).157 Other commonly used criteria are the
Dutch criteria158 and the criteria from the Simon Broome regis-
ter.159 The use of age-related LDL-C levels in the Dutch criteria
does assist the childhood diagnosis.
Childhood screening. High TC levels are present from birth in
HeFH. Because there are few other causes of high cholesterol
in childhood, the finding of increased LDL-C is virtually diagnostic
of HeFH. It is best to avoid measurement of TC in the first 6 weeks
after birth because high levels of HDL-C may obscure the high
LDL-C levels in HeFH. After that, measurement of TC can be vir-
tually diagnostic, unlike in adults. The TC level in childhood rises
until the prepubertal growth spurt, when it declines until the accel-
erated growth subsides, after which it begins to increase to adult
levels. It should, however, be remembered that children in families
where one family member is already affected by HeFH are likely to
be on a particular diet, so borderline cases from such families
should be viewed with caution. It is under these circumstances
that a DNA diagnosis may be most valuable.
Cascade family screening using phenotype. Screening for CVD
risk at the national level generally does not start before the age
of 40–50 years. In cascade family screening an extensive family
history is obtained from patients with definite HeFH attending a
lipid clinic. The family history, which includes contact details of
relatives, is generally taken by a specially trained nurse who then
arranges for lipoprotein profiles on these relatives. The expected
yield of cases is 50% of the relatives screened, which is close
to what is observed in practice. The process can be repeated for
any new cases detected (cascading). The system requires that a
national network of lipid clinics is established and that GPs, cardi-
ologists, and other physicians and nurses are aware of the process
and of the necessity of referring suspected cases to lipid clinics.
Genotyping. Identification of the mutation causing HeFH in indi-
vidual patients is much easier to contemplate when the mutations
likely to be encountered are relatively few in number. Of course,
once the mutation in a particular family has been discovered, the
process of screening other family members becomes easier and
much less costly. Identification of the mutation in the others
would require sequencing of LDLR, PCSK9, and apo
B. Specialized lipid clinics and laboratories can provide this service.
Treatment. It cannot be overemphasized that the management of
HeFH does not simply involve advice about a healthy lifestyle and
the prescription of lipid-lowering drugs, but also involves ensuring
that patients have prompt access to investigations to detect the
presence of significant atherothrombotic disease. Ideally manage-
ment of HeFH should involve a lipid clinic. Lifestyle advice, particu-
larly about diet and the avoidance of smoking, is important in
HeFH.
Drug treatment should be rigorous but should be used
cautiously in women with childbearing potential.155 There seems
no reason to adopt LDL-C targets for statin treatment different
from those in other markedly increased risk patients. It should,
however, be realized that even with maximum doses of therapies,
one cannot expect in patients with particularly high pre-treatment
LDL-C levels to achieve levels ,1.8 mmol/L (less than 70 mg/
dL); a maximal reduction of LDL-C that can be achieved without
side effects should be the target. Generally atorvastatin or rosuvas-
tatin titrated to maximum doses is required. For those whose
LDL-C remains too high despite this, combination therapy
should be considered (see above).
Table 20 lists the recommendations for the detection and treat-
ment of patients with HeFH.
Homozygous familial hypercholesterolaemia. HoFH is rare in
European populations (1 in 106 births) unless there is a
founder gene effect or consanguinity, which is encountered, for
example, in migrants from Asia. Both parents will have HeFH
and there is a one in four chance that a child born to them will
have HoFH. If the heterozygous parents are unrelated, they are
generally unlikely to have the same mutation and thus a child
Table 19 Diagnostic criteria for the clinical diagnosis
of HeFH according to MedPed and WHO158
aPremature CAD: male before 55, women before 60 years of age.
CAD ¼ coronary artery disease; FH ¼ familial hypercholesterolaemia; HeFH ¼
heterozygous familial hypercholesterolaemia; LDL-C ¼ low-density
lipoprotein-cholesterol; Tx ¼ tendon xanthomata: WHO ¼World Health
Organization.
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with the clinical diagnosis of HoFH will in strict genetic terms be a
compounded heterozygote. Regardless of this, HoFH is always an
extremely serious disease, which untreated leads to death typically
in adolescence or early adulthood due to myocardial ischaemia or
aortic stenosis. The worst prognosis occurs when both mutations
lead to complete failure of expression of LDLR rather than to
defective LDLR expression.160 Prenatal diagnosis is possible.
When pregnancy is planned the partners of known cases of
HeFH should have their TC levels checked to exclude the possi-
bility that they also have HeFH.
Affected children develop florid tendon xanthomata and
orange-yellow subcutaneous planar and tuberose xanthomata on
the buttocks, antecubital fossae, knees, and hands, typically in the
webspaces between the fingers. Treatment with statins and LDL
apheresis should be undertaken at a specialist centre from an
early age. MTP inhibitors and apo B antisense approaches might
be used to increase LDL reduction. CABG is frequently necessary
in the late teens or early 20s. If cardiac transplantation is under-
taken, consideration should also be given to liver transplantation
to provide functioning hepatic LDLRs.
10.1.3 Familial dysbetalipoproteinaemia
Familial dysbetalipoproteinaemia (syn. type III hyperlipoproteinae-
mia; remnant removal disease) is rare and is generally inherited
as an autosomal recessive disorder with variable penetrance. It is
rare in women before the menopause. The majority of cases are
homozygous for apo E2. Apo E is important for hepatic clearance
of chylomicron remnants and IDL. Apo E2 binds less readily than
E3 or E4 to hepatic receptors. However, without some coinciden-
tal cause of dyslipidaemia, apo E2 homozygosity does not generally
cause the familial dysbetalipoproteinaemia syndrome. The syn-
drome often develops in the presence of dyslipidaemia associated
with HTG, diabetes mellitus, obesity, or hypothyroidism.
Familial dysbetalipoproteinaemia produces a characteristic clini-
cal syndrome in which both TC and TG are raised before treat-
ment. Patients develop tubero-eruptive xanthomata, particularly
over the elbows and knees, and palmar xanthomata in the skin
creases of their hands and wrists. The risk of CAD is very high,
and accelerated atherosclerosis of the femoral and tibial arteries
is also prevalent. A simple screening test for familial dysbetalipo-
proteinaemia is to measure the ratio of apo B to TC. If this is
,0.15 (using g/L for apo B and mmol/L for TC) familial dysbetali-
poproteinaemia is highly likely.
Generally, the detection of apo E2 homozygosity in a dyslipidae-
mic patient is a reliable confirmation of the diagnosis and can be
easily performed in a specialized lipid clinic. In older patients
with xanthomata resembling those of familial dysbetalipoprotei-
naemia, who prove not to be homozygote for apo E2, a parapro-
tein should be sought.
The treatment of familial dysbetalipoproteinaemia should be
undertaken in a specialist clinic. Many cases respond well to
fibrate and statin drugs, increasingly employed in combination.
10.1.4 Familial lipoprotein lipase deficiency
A profound defect in the catabolism of chylomicrons and VLDL
results in chylomicronaemia and TG levels .15 mmol/L
(1330 mg/dL). It occurs in patients who are homozygous or
compound heterozygote for mutations of the enzyme lipoprotein
lipase (LPL). A similar defect in TG catabolism can be produced by
inheritance of apo C2 deficiency. Mutations of the gene for other
apolipoproteins (apo CIII and apo A5) or interacting proteins are
also emerging as a cause of severe hypertriglyceridaemia.
Familial LPL deficiency is a rare cause of severe HTG which may
cause severe disorders of the pancreas.
10.1.5 Other genetic disorders of lipoprotein metabolism
(see Table 21)
Sometimes patients are encountered with extremely low levels of
LDL-C or HDL-C. The most common genetic hypolipidaemia is
hypobetalipoproteinaemia which is dominantly inherited and
often due to truncation of apo B. Serum LDL-C is typically
between 0.5 and 1.5 mmol/L (20–60 mg/dL). It is generally of
Table 20 Recommendations for detection and
treatment of patients with HeFH
aClass of recommendation.
bLevel of evidence.
CVD ¼ cardiovascular disease; FH ¼ familial hypercholesterolaemia; HeFH ¼
heterozygous familial hypercholesterolaemia; HoFH ¼ homozygous familial
hypercholesterolaemia; LDL-C ¼ low-density lipoprotein-cholesterol.
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no medical significance. A more profound deficiency of apo B
occurs in abetalipoproteinaemia when steatorrhoea, neurological
and other complications require specialist treatment. Almost
absent levels of HDL-C occur in Tangier disease (analphalipopro-
teinaemia) and very low levels of HDL-C occur in lecithin choles-
terol acyltransferase (LCAT) deficiency. Both these conditions are
associated with distinct clinical syndromes and require specialist
investigation. Very high levels of HDL-C are detected in patients
with CETP deficiency. In the heterozygous form, typically levels
of 2.0–2.4 mmol/L (80–90 mg/dL) are observed, and levels of
5 mmol/L (200 mg/dL) or above are observed in homozygotes.
This is not associated with disease.
10.2 Children
Diet is the mainstay of treatment for dyslipidaemia in childhood.
Only in FH should consideration be given to lipid-lowering drug
treatment. In other cases of dyslipidaemia in children, focus
should be on diet and treatment of underlying metabolic disorders.
In the case of HeFH, statin treatment is generally withheld until
sometime between the ages of 10 and 18 years. There is evidence
from carotid ultrasound measurements that increased CIMT com-
pared with siblings who have not inherited HeFH can be detected
from the age of 10 years onwards, and that the progression of
increasing CIMT can be ameliorated with statin therapy and/or
apheresis.161 The exact age at which to start statin treatment is,
however, a matter for clinical judgement. Generally treatment
before the age of 18 years would be indicated in boys with a par-
ticularly adverse family history, because it is known that the age at
which first-degree relatives develop symptomatic CAD is fairly
closely correlated.
Although evidence that statin treatment causes fetal harm is
inconclusive, women should be advised to avoid pregnancy while
they are receiving such treatment. When pregnancy is planned,
the statin should be stopped 3 months before conception is
attempted and not recommenced until breastfeeding has been
completed.
10.3 Women
Among several studies that have evaluated the impact of
lipid-lowering therapy on primary and secondary prevention of
CAD, only a few have included women, usually in small
numbers, and the results have often not been separately reported
by gender.162 The most recent CTT meta-analysis,15 however,
indicates that the benefit overall is similar in men and women.
Primary prevention
Evidence for protective effects of lipid-lowering treatment in high
risk patients without previous CAD has been definitively demon-
strated in men. In contrast, such evidence remains less firm in
women. Two meta-analyses have addressed the effects of different
lipid-lowering treatments on primary prevention of CV events in
women with a broad range of TC from normal to elevated, and
concordantly found no major effects on total mortality and CAD
events in women as opposed to men.15,163 A more recent
meta-analysis that included the large female subgroup from the
JUPITER trial reported a 12% relative risk reduction (RRR) of
total mortality with statin use in high risk subjects without estab-
lished CVD, with no heterogeneity in treatment effect between
men and women.16 Thus, statin use should be considered for
primary prevention in women at high CV risk with the same
indications as for men.
Secondary prevention
More data coming from large RCTs of secondary prevention are
available for women. The results of these trials concordantly
showed that lipid-lowering therapy substantially reduces CV
events in these patients, although no reduction in total mortality
risk could be demonstrated.164 The meta-analysis of Walsh
et al.164 reported, in a cohort of 8272 females with previous
CVD mainly treated with statins, a 26% reduction of CV mortality,
a 29% reduction of MI, and a 20% reduction of total CAD events.
The CTT meta-analysis also indicates that the benefit overall is
similar in men and women.15 Therefore, secondary prevention of
CV events in women should routinely include a statin-based
lipid-lowering regimen, with the same recommendations and
therapeutic targets that are applied to men.
Non-statin lipid-lowering drugs
The role of other pharmacological treatments for primary and sec-
ondary prevention of CAD in women remains undetermined. In
particular, nicotinic acid, ezetimibe, or fibrates, alone or in combi-
nation with statins, can be used, depending on the type of
Table 21 Genetic disorders of lipoprotein
metabolism
FH ¼ familial hypercholesterolaemia; HeFH ¼ heterozygous familial
hypercholesterolaemia; HoFH ¼ homozygous familial hypercholesterolaemia;
HDL ¼ high-density lipoprotein; IDL ¼ intermediate-density lipoprotein;
LCAT ¼ lecithin cholesterol acyltransferase; LDL ¼ low-density lipoprotein;
VLDL ¼ very low density lipoprotein.
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dyslipidaemia and side effect profiles, although no definitive evi-
dence of cardioprotective effects is available.
Hormone therapy
Currently used third-generation low oestrogen–progestin dose
oral contraceptives do not appear to increase adverse coronary
events, and can be used, after baseline lipid profile assessment, in
women with acceptable TC levels. In contrast, alternative
contraceptive measures should be recommended in women with
hypercholesterolaemia (LDL-C .4 mmol/L, more than
160 mg/dL), or with multiple risk factors and in those at high
risk of thrombotic events.165 Oestrogen replacement therapy,
despite some favourable effects on the lipid profile, has not been
demonstrated to reduce CV risk and cannot be recommended
for CV prevention in women.166
No lipid-lowering drugs should be administered during preg-
nancy and the period of breastfeeding because data on possible
adverse effects are lacking.
Table 22 lists the main measures in the management of
dyslipidaemia in women.
10.4 The elderly
The proportion of elderly people in society is increasing. More
than 80% of individuals who die of CAD are older than 65 years.
Smoking, hypertension, hyperlipidaemia, and diabetes mellitus are
leading risk factors for CVD at all ages, but the absolute risk
increases exponentially with advancing age.
Risk reduction in individuals older than 65 years is essential
because two-thirds to three-quarters of them have either clinical
CAD or subclinical atherosclerotic disease. Almost 25% of men
and 42% of women older than 65 years have a TC level
.6 mmol/L (more than 240 mg/dL). According to published
data, elderly individuals are a high risk group who could benefit sig-
nificantly from lipid-lowering therapy to reduce CV morbidity and
mortality.15 Evidence for treatment above the age of 80–85 years
is very limited, and clinical judgement should guide decisions in the
very old.
Primary prevention
The optimal approach is lifetime prevention and the goal is to
reduce the total burden of CVD in the population. Lifetime pre-
vention includes no smoking, healthy eating habits, regular exer-
cise, and eliminating excess body weight. Primary prevention
measures in the elderly should not differ from those undertaken
in younger subjects. In fact, although there is no evidence that
hypolipidaemic treatment in elderly people prolongs life in patients
without previous CVD, treatment reduces CV morbidity (stroke,
MI) in elderly people in primary prevention.16 The Prospective
Study of Pravastatin in the Elderly at Risk (PROSPER) was the
first trial to evaluate older people prospectively. Patients
between 70 and 82 years of age who had a history of risk
factors for vascular disease were randomized to pravastatin
40 mg/day or placebo. After 3 years of follow-up, pravastatin
reduced LDL-C levels by 34%, TG by 13%, and the risk from cor-
onary death, non-fatal MI, and stroke by 15%. It could not reduce
total mortality or improve cognitive dysfunction.26 The CTT
meta-analysis showed no significant differences in RRR between
younger and older people,15 and neither did a recent meta-analysis
of primary prevention trials.16
Secondary prevention
Despite including few elderly participants, multiple prospective
clinical trials have shown good outcomes of lipid-lowering
therapy in elderly patients with CAD.15 The Scandinavian Simvas-
tatin Survival Study (4S) showed that simvastatin decreased total
mortality by 35% and coronary mortality by 42% in both sexes
and in individuals aged ≥60 years over 5 years.18 The Cholesterol
and Recurrent Events (CARE) trial evaluated the effect of pravas-
tatin on coronary events after MI and showed major coronary
events, coronary death, and stroke were reduced by, respectively,
32, 45, and 40% in elderly patients; the number needed to treat
(NNT) of older patients for 5 years was 11 in order to prevent
one major coronary event and 22 to prevent one coronary
death.20
Results from an MI registry study in Sweden demonstrate that
statin treatment is associated with lower CV mortality in very
elderly post-MI patients without increasing the risk of the
development of cancer.167
Side effects and interactions
The safety and side effects of statins are a matter of special concern
in the elderly because older adults often have co-morbidities, take
multiple medications, and have altered pharmacokinetics and phar-
macodynamics. Statin–drug interactions are a concern primarily
because of their potential to increase statin-associated side
effects such as myalgia without CK elevation, myopathy with CK
elevation, and the rare but serious rhabdomyolysis with marked
CK elevation. Medication should be started at a low dose to
avoid adverse events, and then titrated to achieve optimal
LDL-C levels with an appropriate dose.
Adherence
Elderly individuals are less likely to receive lipid-lowering medi-
cations or adhere to statin therapy. Cost, adverse effects, coronary
events occurring despite being on lipid-lowering agents, and the
perception that the drug is not beneficial may be the reasons for
non-compliance. Improving patient understanding of CV risk, the
medication regimen, and potential benefits of persistence with
statin therapy may further enhance compliance.
Table 22 Management of dyslipidaemia in women
CAD ¼ coronary artery disease.
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Table 23 lists the recommendations for treatment of
dyslipidaemia in the elderly.
10.5 Metabolic syndrome and diabetes
The term MetS refers to the tendency for certain risk factors to
cluster together: central obesity, raised serum TG, reduced
HDL-C, glucose intolerance, and hypertension. Scoring systems
which dichotomize these variables, and require, for instance,
three out of five to make a diagnosis, may miss some of the associ-
ated risk; a practical approach is that if one component is identified,
a systematic search should be made for others.
MetS identifies people at a higher risk of CVD than the general
population. Data from recent meta-analyses indicate that people
with MetS have a 2-fold increase in CV outcomes and 1.5-fold
increase in all-cause mortality.168 How to capture the extra risk
beyond the traditional risk factors in clinical practice is a debated
issue; even the definition of MetS is not fully harmonized. A com-
bination of high waist circumference and elevation of TG is a
simple and inexpensive screening tool to discriminate people
with MetS at high CVD risk for global risk evaluation.95
Since CVD is the major cause of both morbidity and mortality in
people with diabetes, the global epidemic of type 2 diabetes fore-
sees a daunting increase of CVD. Diabetes itself is an independent
risk factor for CVD and is associated with higher risk of CVD, even
more so in women. Hypertension, dyslipidaemia, and abdominal
obesity commonly co-exist with type 2 diabetes and further aggra-
vate the risk that is highest in people with type 2 diabetes and fea-
tures of MetS.169 Importantly, diabetes confers excess mortality
risk following ACS despite modern therapies highlighting the
poor prognosis of coronary patients with type 2 diabetes170 and
the need for aggressive therapy.
Specific features of dyslipidaemia in insulin resistance
and type 2 diabetes
Diabetic dyslipidaemia is a cluster of plasma lipid and lipoprotein
abnormalities that are metabolically interrelated. HTG or low
HDL-C or both is seen in about half of subjects with type 2 dia-
betes. The increase in large VLDL particles in type 2 diabetes
initiates a sequence of events that generates atherogenic remnants,
small dense LDL and small dense HDL particles.171 These com-
ponents are not isolated abnormalities but are metabolically
closely linked to each other. Together these components comprise
the atherogenic lipid triad that is also characterized by an increase
in apo B concentration due to an increased number of apo B-
containing particles. Importantly, TRLs including chylomicrons,
VLDL, and their remnants carry a single apo B molecule, also
like LDL particles. Therefore, the malignant nature of diabetic dys-
lipidaemia is not always revealed by the lipid measures used in clini-
cal practice as LDL-C remains within the normal range. Elevation
of TG or low HDL-C is seen in about half of subjects with type
2 diabetes.172 The abnormal features of the lipid profile precede
type 2 diabetes by several years and are common in subjects
with central obesity, MetS, and type 2 diabetes.
Table 24 summarizes the role of dyslipidaemia in MetS and type
2 diabetes.
Treatment strategies for subjects with type 2 diabetes
and metabolic syndrome
Lifestyle therapy to improve the atherogenic lipid profile should be
recommended to all subjects with type 2 diabetes and MetS.173
Dietary advice should be tailored according to individuals needs.
If targets are not achieved on maximally tolerated doses of
statins, drug combinations may offer additional lowering of
LDL-C, but the evidence from outcome studies is limited.
Patients with type 2 diabetes younger than 40 years, with a short
duration of therapy, without other risk factors, without
Table 23 Recommendations for treatment of




CV ¼ cardiovascular; CVD ¼ cardiovascular disease.
Table 24 Summary of dyslipidaemia in MetS and in
type 2 diabetes
apo ¼ apolipoprotein; CVD ¼ cardiovascular disease; HDL-C ¼ high-density
lipoprotein-cholesterol; LDL ¼ low-density lipoprotein; MetS ¼ metabolic
syndrome; TG ¼ triglyceride; TRLs ¼ trigyceride-rich lipoproteins.
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complications, and with an LDL-C level ,2.5 mmol/L (,100 mg/
dL) may not need lipid-lowering drugs.
Evidence for lipid-lowering therapy
Low-density lipoprotein-cholesterol
Trials specifically performed in subjects with type 2 diabetes as
well as subsets of individuals with diabetes in major statin trials
have consistently demonstrated significant benefits of statin
therapy on CVD events in people with type 2 diabetes.15 Statin
therapy reduces the 5 year incidence of major CVD events by
20% per mmol/L reduction in LDL-C regardless of initial
LDL-C or other baseline characteristics based on meta-analysis.15
The CTT meta-analysis further indicates that subjects with type
2 diabetes will benefit from cholesterol-lowering therapy in RRR
to a similar degree as non-diabetic patients, but being at higher
absolute risk the absolute benefit will be greater resulting in a
lower NNT. Recent studies have suggested an increased incidence
of diabetes in patients treated with statins.101 This effect must not
lessen our attention to the treatment of patients as the overall
benefit in CV events reduction still remains.
Triglycerides and high-density lipoprotein-cholesterol
Recent data from patients with type 2 diabetes in the FIELD study
revealed that traditional lipid ratios (non-HDL-C/HDL-C, TC/
HDL-C) were as strong predictors for CVD risk as the apo B/apo
A1 ratio, and captured the impact of both atherogenic and anti-
atherogenic particles on CVD risk.47 Clinical benefits achieved by
treatment of the atherogenic dyslipidaemia (high TG and low
HDL-C) are still a matter of discussion. The FIELD trial failed to
reduce significantly the primary endpoint of CAD events (CAD
death or non-fatal MI). CVD events were reduced significantly by
11%. In a post-hoc analysis of the FIELD study, fenofibrate reduced
CVD events by 27% in those with raised TG (.2.3 mmol/L or
more than 204 mg/dL) and reduced HDL-C (NNT ¼ 23).172
The ACCORD trial has confirmed this: patients who had both TG
levels in the higher third (≥2.3 mmol/L, ≥204 mg/dL) and an
HDL-C level below the lower third (≤0.88 mmol/L, ≤34 mg/
dL)—representing 17% of all participants—appeared to benefit
from adding fenofibrate to simvastatin.141
A post-hoc analysis of patients with low HDL-C ,1 mmol/L
(less than 40 mg/dL) and elevated TG .1.80 mmol/L (more
than 160 mg/dL) in the 4S trial demonstrated a relative risk for
major coronary events of 0.48 with simvastatin. The respective
relative risk for overall mortality was 0.44.174 Consistent with
these findings, a meta-analysis of fibrates in the prevention of
CVD in 11 590 people with type 2 diabetes showed that fibrates
reduced the risk of non-fatal MI significantly by 21%, but had
no effect on the risk of overall mortality or coronary mortality.175
The concept of raising HDL-C seems attractive based on the
strength of the relationship between low HDL-C and increased
CVD risk in observational studies. The available tools to raise
HDL-C in clinical practice are limited, lifestyle modification
providing the first option. At present, nicotinic acid provides the
best drug strategy to raise HDL-C, although fibrates can also be
used. The impairment of glycaemic control by nicotinic acid is
seen at high doses, but at modest doses glycaemic control can in
general be maintained by adjustment of diabetes therapy.176
Type 1 diabetes
Type 1 diabetes is associated with high CVD risk, in particular in
patients with microalbuminuria and renal disease.177 Conclusive
evidence supports the proposition that hyperglycaemia accelerates
atherosclerosis.
The lipid profile in type 1 diabetic subjects with good glycaemic
control is ‘supernormal’ and characterized by subnormal TG and
LDL-C, whereas HDL-C is usually within the upper normal
range or slightly elevated. This is explained by administration of
subcutaneous insulin therapy that increases LPL activity in
adipose tissue and skeletal muscle and consequently the turnover
rate of VLDL particles. However, there are potentially atherogenic
changes in the composition of both HDL and LDL particles. In all
patients with type 1 diabetes and in the presence of microalbumi-
nuria and renal disease, LDL-C lowering (at least 30%) with statins
as the first choice (eventually drug combination) is recommended
irrespective of the basal LDL-C concentration.
Recommendations for the treatment of dyslipidaemia in diabetes
are shown in Table 25.
10.6 Patients with acute coronary
syndrome and patients undergoing
percutaneous coronary intervention
Patients who have presented recently with an ACS are at high risk
of experiencing further CV events. In these patients, lipid manage-
ment should be undertaken in the context of a comprehensive
global risk management strategy that includes lifestyle adaptations,





apo ¼ apolipoprotein; CKD ¼ chronic kidney disease; CVD ¼ cardiovascular
disease; LDL-C ¼ low-density lipoprotein-cholesterol.
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management of risk factors, and the use of cardioprotective
drugs in certain subgroups. Ideally, this can be well coordinated
through participation in a multidisciplinary cardiac rehabilitation
programme.
Specific lipid management issues in acute coronary
syndrome
Data from specific trials23,30,35 and meta-analysis support routine
early use of prompt and intensive statin therapy. Thus, we rec-
ommend that high dose statin therapy be initiated during the
first 1–4 days of hospitalization for the index ACS; if basal
LDL-C values are known, the dose should aim at reaching the
LDL-C target of ,1.8 mmol/L (less than 70 mg/dL). The use
of lower intensity statin therapy should be considered in patients
at increased risk of side effects with high doses of statin (e.g. the
elderly, hepatic impairment, renal impairment, or potential for
interaction with essential concomitant therapy). Lipids should be
re-evaluated 4–6 weeks after the ACS to determine whether
target levels have been reached and regarding safety issues; the
statin dose can then be adapted accordingly.
The consumption of n-3 PUFAs, as either increased (oily) fish
intake or a highly purified n-3 acid ethyl ester prescription medi-
cation, has in one study been shown to reduce mortality in survi-
vors of MI,178 but not in another.92 Post-hoc analysis of the GISSI-P
(Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto
Miocardico-Prevenzione) study has shown particular benefit from
highly purified n-3 supplementation in those post-MI patients
with left ventricular dysfunction who are at an increased risk of
mortality. However, this cannot be attributed to their antilipidae-
mic effect but predominantly to their antiarrhythmic effects.
Lipid management issues in patients undergoing
percutaneous coronary intervention
Short-term pre-treatment with atorvastatin reduces the extent of
MI during PCI in statin-naı¨ve patients with both stable angina and
ACS. More recently, the Atorvastatin for Reduction of Myocardial
Damage during Angioplasty (ARMYDA)179 trial demonstrated that
reloading with high dose atorvastatin reduces the frequency of
periprocedural MI, even in patients receiving chronic statin
therapy undergoing PCI for management of stable angina or
low–intermediate risk ACS. Thus, a strategy of routine reload
with high intensity statin shortly before PCI may be considered
even on the background of chronic therapy (class IIb B179).
10.7 Heart failure and valvular diseases
Prevention of incident heart failure in coronary artery
disease patients
Onset of heart failure (HF) increases the risk of mortality and mor-
bidity 3–4 times compared with patients without HF. Pooling of
results from RCTs suggested that cholesterol lowering with
statin treatment reduced incident HF by 9–45% in patients with
CAD.22,180
Five key prospective RCTs compared more intensive vs. less
intensive drug regimens. The more intense approach reduced the
incidence of hospitalization due to HF by an average of 27% (P
,0.0001) in patients with acute and stable CAD without previous
HF. This demonstrated that a more intensive statin therapy is more
effective than less intensive statin therapy for prevention of inci-
dent HF.23,26,181–183 However, there is no evidence that statins
can prevent HF in patients with non-ischaemic cardiomyopathy.
Chronic heart failure
HF patients have lower TC and LDL-C than patients without HF. In
contrast to patients without HF, a low TC portends a poor prog-
nosis in HF. Although non-controlled observational studies have
shown favourable effects among statin users in HF trials, RCT
studies do not support this notion. Observational studies are
subject to confounding, and treatment with statins should not be
started in patients with moderate to severe HF [New York
Heart Association (NYHA) classification III– IV].36,39 However,
there is no evidence for harm in patients on statin treatment
after the occurrence of HF. The Controlled Rosuvastatin Multina-
tional Study in Heart Failure (CORONA) and Gruppo Italiano per
lo Studio della Sopravivenza nell’Infarto Miocardico-Effect of Rosu-
vastatin in Patients with Chronic Heart Failure (GISSI-HF) trials in
patients with symptomatic HF did not demonstrate any benefit on
CV mortality and non-fatal MI and stroke, in spite of a marked
reduction of LDL-C and hs-CRP.36,39
One RCT has demonstrated a small but significant effect of n-3
PUFAs on primary endpoints (all-cause death and hospitalization
for HF).184 This effect was significant only after adjustment for
baseline imbalance between randomized groups.
Valvular disease
There is an association between aortic stenosis, LDL-C, and Lp(a),
and also between aortic stenosis and increased risk for CV events
and mortality. There is also suggestive evidence for an association
between cholesterol and increased risk for calcification of biopros-
thetic valves. Early observational non-controlled trials show ben-
eficial effects of aggressive lipid lowering in slowing the
progression of aortic stenosis. This was not confirmed in a
recent RCT, yet the CAD was significantly reduced.38
The SEAS trial randomized 1873 patients with mild to moderate
asymptomatic aortic stenosis to the combination of simvastatin
40 mg plus ezetemibe 10 mg, and simvastatin 40 mg alone.
Despite marked LDL-C lowering (61%), progression of aortic ste-
nosis was similar in the two treatment groups.38 Ischaemic events
were reduced by 21%. One small observational study suggested a
benefit of statin treatment among patients with bioprosthetic
valves.185
Table 26 lists the recommendations for treatment of dyslipidae-
mia in HF or valvular disease.
10.8 Autoimmune diseases
Autoimmune diseases, including rheumatoid arthritis, SLE, psoria-
sis, and antiphospholipid syndrome, are characterized by enhanced
atherosclerosis and consequently higher CV morbidity and
mortality rates compared with the general population.186–188
The immune system is believed to be involved in the pathogen-
esis of atherosclerosis. Inflammatory components of the immune
response, as well as autoimmune elements (e.g. autoantibodies,
autoantigens, and autoreactive lymphocytes) are involved in
these processes. The diseases are characterized by inflammatory
vasculitis and endothelial dysfunction.
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Table 27 lists the recommendations for the treatment of
dyslipidaemia in autoimmune diseases.
10.9 Renal disease
The prevalence of CKD, in particular mild to moderate CKD, is
rapidly increasing worldwide. A decreasing GFR is associated
with CVD independently of other risk factors.189 In a recent
survey in Europe the standardized CV mortality rate was 38 per
1000 person years (95% CI 37.2–39.0) higher in patients starting
dialysis than in the general population.190
Lipoprotein profile in chronic kidney disease
The lipid profile shows both quantitative and qualitative abnormal-
ities that worsen with declining GFR, being most pronounced in
subjects with end-stage renal disease (ESRD). Dyslipidaemia
comprises typically elevations of TG and lowering of HDL-C,
whereas the changes of TC and LDL-C are less marked in stage
1–2 CKD. The elevation of TG is caused by both increased
production and impaired removal of TRLs dues to changes in
regulatory enzymes and proteins. Consequently non-HDL-C and
apo B levels are clearly increased. LDL subclasses display a shift
to excess of small dense LDL particles. In patients with ESRD
the catabolic rate of LDL is markedly prolonged, resulting in
clear elevation of both TC and LDL-C levels. Plasma Lp(a) levels
also start to increase early due to the prolonged residence times
of these particles in the circulation. Altogether, most patients
with stage 3–5 CKD have mixed dyslipidaemia and the lipid
profile is highly atherogenic with adverse changes in all
lipoproteins.
Evidence for lipid management in patients with chronic
kidney disease
Available data from post-hoc analyses of statin trials provide evi-
dence for the beneficial effects of statin therapy on CVD outcomes
in patients with stages 2 and 3 CKD. The Pravastatin Pooling
Project (PPP) included 19 737 subjects with a median follow-up
of 64 months.191 The benefit was most marked in subjects with
both CKD and diabetes. Notably there was also a significant
reduction in the risk of all-cause mortality (relative risk 0.81,
95% CI 0.73–0.89). In the Heart Protection Study (HPS) the absol-
ute risk reduction was 11% in a subgroup of subjects with mild
CKD as compared with 5.4% in the total cohort.192
The results from patients with more advanced CKD (stage 4–5)
and on dialysis are less clear. Two observational studies have
reported benefits of statin use in subjects on haemodialysis.
However, in the Die Deutsche Diabetes Dialyse studie (4D)
trial31 in a cohort of 1200 patients with diabetes on haemodialysis,
atorvastatin had no positive effect on the primary composite end-
point of CVD. The results from AURORA (A study to evaluate the
Use of Rosuvastatin in subjects On Regular haemodialysis: an
Assessment of survival and cardiovascular events) involving 2776
patients on haemodialysis40 show that rosuvastatin lowered
LDL-C as expected but had no significant effect on the composite
CVD endpoint. These negative results question the benefits of
statins in these very high risk patients with poor outcomes.
SHARP reported results in 9500 high risk subjects with CKD.
Major atherosclerotic events were reduced by 17% (P ¼ 0.0022)
and major vascular events by 15.3% (P ¼ 0.0012) in patients on
ezetimibe plus simvastatin as compared with placebo.111 Impor-
tantly, although no significant heterogeneity existed between
non-dialysis and dialysis subjects, this was also true for placebo
vs. dialysis subjects.
Therapeutic targets for patients with chronic kidney
disease
CKD is acknowledged as a CAD risk equivalent. This has set the
LDL-C reductions as the primary target of therapy. Non-HDL-C
should be the second objective in the management of mixed
dyslipidaemia. The treatment algorithm should be based on GFR.
Drugs eliminated mainly by the hepatic route should be preferred
(fluvastatin, atorvastatin, pitavastatin, and ezetimibe). Statins
metabolized via CYP3A4 may result in adverse effects due to
drug–drug interactions, and special caution is required.
Table 28 lists the recommendations for lipid-lowering drugs in
patients with moderate to severe CKD.
Table 27 Recommendations for treatment of
dyslipidaemia in autoimmune diseases
aClass of recommendation.
bLevel of evidence.
Table 26 Recommendations for treatment of
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Lipid management in kidney failure (stage 5, glomerular
filtration rate <15 mL/min/1.73 m2)
The use of statins with limited renal excretion is mandatory at low
doses. The use of prescription n-3 fatty acids to lower TG is an
option.
Safety of lipid management in patients with chronic
kidney disease
Statins are generally well tolerated at moderate doses in subjects
with CKD stages 1–2. Safety issues and dose adjustment
become important in more advanced stages of CKD (stages
3–5), as adverse events are commonly dose related and due to
increased blood concentration of the compound. Statins with
minimal renal excretion should be the drug of choice (atorvastatin,
fluvastatin, and pitavastatin).
Growing evidence indicates that fibrates increase serum creati-
nine and homocysteine, both being established CVD risk factors.
Effects of fenofibrate are more pronounced than those of gemfi-
brozil. As fibrates have no effect on creatinine excretion into
urine, the estimation of GFR is hampered by the rise of creatinine
and is a problem in clinical practice. Fenofibrate is also non-
dialysable and should not be used in patients with GFR ,50 mL/
min/1.73 m2. The dose of gemfibrozil is recommended to be
reduced to 600 mg/day if GFR is ,60 mL/ml/1.73 m2 and
avoided if GFR is ,15 mL/min/1.73 m2.
Recently the availability of prescription brand n-3 fatty acids pro-
vides an option to lower TG in patients with mixed dyslipidaemia.
10.10 Transplantation patients
Lipid abnormalities are common in patients who have undergone
solid organ transplantation, and predispose to the development
of both atherosclerotic disease and transplant arterial vasculopa-
thy, resulting in major vascular events.
Common general causes of dyslipidaemia in these patients are
diabetes, obesity, MetS, and CKD.
Immunosuppressive drug regimens also have important adverse
effects on lipid metabolism. Glucocorticoid therapy causes weight
gain and exacerbates insulin resistance, leading to increases in TC,
VLDL, and TG, and in the size and density of LDL particles. Calci-
neurin inhibitors increase the activity of hepatic lipase, decrease
LPL, and bind the LDLR, resulting in reduced clearance of athero-
genic lipoproteins. A greater adverse impact on lipid profiles is
seen with ciclosporin than with tacrolimus. Sirolimus, a structural
analogue of tacrolimus, causes dyslipidaemia in almost half of the
patients receiving it. Patients should receive healthy lifestyle
advice as recommended for patients at increased risk of CVD.
Statins have a similar effect on lipids in transplant recipients as in
the general population. Although randomized trial data have
shown that statins have the potential to improve outcomes in
heart transplant patients195–197 and renal transplant patients,198
the amounts of outcome data are not extensive. A recent systema-
tic review demonstrated a strong trend to reduced CVD events
and mortality with statins in renal transplant patients.198
Several potential drug interactions must also be considered,
especially with ciclosporin which is metabolized through
CYP3A4 and may increase systemic statin exposure and the risk
of myopathy. Fluvastatin, pravastatin, pitavastatin, and rosuvastatin
have less potential for interaction.197 Tacrolimus is also metab-
olized by CYP3A4 but appears to have less potential for harmful
interaction with statins than ciclosporin. Other drugs that influence
CYP3A4 activity should be avoided if possible and used with
extreme caution in patients receiving both calcineurin inhibitors
and statins.
Statins are recommended as the first-line agents for lipid lower-
ing in transplant patients. Initiation should be at low doses with
careful up-titration and caution regarding potential drug–drug
interactions. Initiation of therapy with low dose pravastatin or flu-
vastatin is recommended for those on ciclosporin.
For those with dyslipidaemia who are unable to take statins, eze-
timibe could be considered as an alternative in those with high
LDL-C,199 and nicotinic acid might be considered for lowering
TG and raising HDL-C. No outcome data are available for these
drugs, which should generally be reserved for second-line use.
Care is required with use of fibrates as they can decrease ciclos-
porin levels and have the potential to cause myopathy. Extreme
caution is required if fibrate therapy is planned in combination
with a statin. Cholestyramine is not effective as a monotherapy
Table 28 Recommendations for lipid lowering drugs
in patients with moderate to severe CKD (stages 2–4,




CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; ESRD ¼
end-stage renal disease; GFR ¼ glomerular filtration rate; LDL-C ¼ low-density
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in heart transplant patients and has the potential to reduce absorp-
tion of immunosuppressants, minimized by separate administration.
Table 29 lists the recommendations for treatment of dyslipidae-
mia in transplant patients.
10.11 Peripheral arterial disease
PAD is a common manifestation of atherosclerosis and may involve
several vascular sites, including the carotid district, the aorta, the
lower limb arteries, and, more rarely, the renal and mesenteric
arterial vessels. Patients with PAD are at elevated risk of coronary
events, and the presence of peripheral vascular atherosclerosis
represents an independent risk factor for MI and CV
death.200,201 Elevated CV risk has led to inclusion of PAD among
the list of ‘risk equivalent’ conditions, and therapeutic strategies
of secondary prevention should be implemented. Yet, despite
the high CV morbidity and mortality risk, PAD patients are
usually inadequately managed compared with CAD patients.200
Occlusive arterial disease of the lower limbs
Cholesterol-lowering therapy reduces the risk of ischaemic CV
events and worsening of claudication, and improves walking
performance.
As for cardiac events, a recent systematic review202 of 18 trials
including .10 000 patients, with cholesterol levels from normal to
elevated, reported that lipid-lowering therapy in subjects affected
by atherosclerosis of the lower limbs is associated with a 20%
reduction in total CV events, together with a non-significant 14%
reduction of all-cause mortality.
Carotid artery disease
Several trials have shown the beneficial effects of lipid-lowering
therapy on the progression of CIMT and on the prevention of
CV events. A meta-analysis of 10 studies including 3443 patients203
reported a significant reduction in the progression of carotid ather-
osclerosis in statin-treated patients compared with placebo, and a
more recent systematic review also showed a significant CIMT
regression after statin therapy.204 In a meta-analysis of RCTs enrol-
ling .90 000 patients, Amarenco et al. reported that statin therapy
determines a 21% reduction in the incidence of all strokes in differ-
ent populations, with a strong correlation between LDL-C
reduction and CIMT, pointing to a 0.73% per year reduction of
CIMT for each 10% decrease of LDL-C.205 Recent studies also
suggest that nicotinic acid may add to the protective effect of
statins.131
However, there are currently no randomized studies that have
assessed whether lipid-lowering treatments reduce the incidence
of CV events in patients enrolled on the basis of carotid athero-
sclerotic disease and without previous CV events.
Retinal artery atherosclerosis
Atherosclerotic changes of retinal arteries correlate with TC,
LDL-C, TG, and apo B levels and also with CAD. However,
there are no studies assessing whether lipid-lowering treatments
reduce these changes.206
Secondary prevention in patients with aortic abdominal
aneurysm
Although the presence of abdominal aortic aneurysm represents a
risk equivalent condition, there are currently no available clinical
trials on CV risk reduction in patients affected by this condition.
Two systematic reviews,204,207 mostly based on retrospective non-
randomized studies, reported that there is still inconclusive evi-
dence that statin therapy reduces the perioperative CV morbidity
and mortality in these patients. In an RCT comparing atorvastatin
20 mg with placebo, the composite endpoint of cardiac death,
MI, stroke, and unstable angina was significantly reduced in 100
patients undergoing vascular non-cardiac surgery, including
abdominal aortic aneurysm repair.208 In another double-blind
placebo-controlled trial in 497 patients undergoing vascular
surgery, perioperative fluvastatin therapy (80 mg/day) was associ-
ated with an improvement in post-operative cardiac outcome.209
Lipid-lowering therapy has never been tested in patients affected
by renovascular atherosclerosis. Yet, despite lack of clinical trials,
statin treatment should be considered for patients affected by
aortic atherosclerotic disease.
The recommendations for lipid-lowering drugs in patients with
PAD are shown in Table 30.
Table 29 Recommendations for treatment of
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Stroke has a heterogeneous aetiology including cardiac
thrombo-embolism (often associated with atrial fibrillation),
carotid artery and proximal aortic atherosclerosis and
thrombo-embolism, small vessel cerebrovascular disease, and
intracranial haemorrhage (including intracerebral and subarachnoid
haemorrhage). Dyslipidaemia may play a variable role in the patho-
genesis of stroke according to the particular aetiology. The
relationship between dyslipidaemia and atherothrombotic events
including ischaemic stroke and transient ischaemic attack (TIA) is
well recognized, while the association of dyslipidaemia with
other types of stroke is uncertain.
Primary prevention
The use of cholesterol-lowering therapy in adults at high risk of
CVD due to LDL-C or other CV risk factors, including arterial
hypertension, reduces the risk of stroke or TIA.26,30,33,210,211
More intensive lipid lowering with statins is associated with
lower risk of stroke compared with less intensive regimens.210
Primary prevention of stroke contributes to the overall indi-
cation for starting treatment with statins in all patients with estab-
lished atherosclerotic disease and in patients at high risk for
developing CVD.
Statin therapy28,32,37 should be considered for reducing the risk
of ischaemic stroke and other CV events in accordance with the
recommendations given in Table 3. The value of other
lipid-lowering therapies in the primary prevention of stroke is
uncertain.
Secondary prevention
Following stroke or TIA,34 patients are at risk not only of recurrent
cerebrovascular events but also of other major CV events includ-
ing MI. Secondary prevention therapy with statins reduces the risk
of stroke, MI, and vascular death. However, the aetiology of stroke
may influence the response to statins, and those patients with evi-
dence of atherothrombosis underlying their cerebrovascular
events appear to benefit most, while those with haemorrhagic
stroke may not benefit or may even be harmed by statins,
particularly if patients do not have evidence of atherosclerotic
disease.210
A recent meta-analysis suggests that nicotinic acid alone or in
combination with statin may add further benefit in stroke
prevention.133
Table 31 lists the recommendations for lipid-lowering drugs for
primary and secondary prevention of stroke.
10.13 Human immunodeficiency virus
patients
Human immunodeficiency virus (HIV)-infected patients often
have low TC and LDL-C as well as low HDL-C and increased
TG. Highly active antiretroviral treatment (HAART) causes an
increase of LDL-C and TG, and predominance of small, dense
LDL particles, thus doubling their CAD risk when compared
with HIV-negative subjects.212 Since HAART also increases
blood pressure and insulin resistance, this could contribute to
the increased CAD risk too. Lipoprotein metabolism is influenced
to a lesser extent by nucleoside reverse transcriptase inhibitors
and non-nucleoside reverse transcriptase inhibitors. HAART,
including protease inhibitors, may particularly accelerate the
onset of CAD-related events in young male heavy smokers
with dyslipidaemia.
Dietary changes and regular physical activity as well as switching
to another HAART regimen may act favourably on dyslipidaemia,
but most patients still need pharmacological therapy to reach the
lipid goals. There were safety concerns because of potential inter-
actions for the association of lipid-lowering drugs with HAART.
However, no significant toxicity has been observed and statins
are the treatment of choice for increased LDL-C, while fibrates
Table 31 Recommendations for lipid-lowering drugs
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may be prescribed when HTG is predominant.213 Different statin
brands could have different interactions with HAART; according
to the European AIDS Clinical Society simvastatin is contraindi-
cated in patients receiving ritonavir-boosted protease inhibitor-
based antiretroviral treatment214; the combination of rosuvastatin
with lopinavir/ritonavir should also be used with caution.215 For
patients who cannot tolerate statin treatment, ezetimibe could
be an option.216 Use of bile acid sequestrants is not recommended
because they increase TG and their effects on the absorption of
antiretroviral drugs have not been studied.
There are no data on effects of statins, ezetimibe, nicotinic acid,
or fibrates on CV events in dyslipidaemic HIV-infected patients.
The recommendations for lipid-lowering drugs in HIV patients
are shown in Table 32.
11. Monitoring of lipids and
enzymes in patients on
lipid-lowering drug therapy
Evidence for what tests should be carried out to monitor lipids in
patients on treatment is limited. Similar limited evidence applies to
tests of possible toxicity such as ALT and CK. Recommendations
stem from consensus rather than evidence-based guidelines.
Response to therapy can be assessed at 6–8 weeks from
initiation or dose increases for statins, but response to fibrates
and lifestyle may take longer. Standard practice for subsequent
follow-up monitoring is 6–12 months, but such monitoring inter-
vals are arbitrary. As a minimum, TC should be assessed, but better
management decisions will probably occur if a full lipid profile is
performed including HDL-C, TG, and LDL-C. Epidemiological
studies show that non-HDL-C and apo B measurement may corre-
late modestly better with outcomes, but there are no data on the
use in routine clinical settings.
A separate issue is the impact of regular lipid monitoring in pro-
moting patient adherence to lifestyle changes or drug regimens
that impact positively on their health, as found in a range of
studies.217 It is unclear if only the process of monitoring is critical
in achieving this, or a combination of education, regular contact,
and adherence assessment.




HIV ¼ human immunodeficiency virus; LDL-C ¼ low-density
lipoprotein-cholesterol.
Table 33 Summary of recommendations for
monitoring lipids and enzymes in patients on
lipid-lowering therapy
ACS ¼ acute coronary syndrome; ALT ¼ alanine aminotransferase; CK ¼
creatine phosphokinase; ULN ¼ upper limit of normal.
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Where statins are used, safety blood tests are advised by regula-
tors, including ALT and CK at baseline to identify the limited
number of patients where treatment is contraindicated. CK
should at least be checked in patients with high risk for myopathy
such as the very elderly with co-morbidities, patients with earlier
muscle symptoms, or patients on interacting drugs. Follow-up is
advised at 6 or 12 monthly intervals to monitor potential toxic
side effects, but such assessments have a limited scientific basis.
A systematic review218 found that the incidence of drug-induced
hepatotoxicity in patients taking lipid-lowering drugs is unknown,
with few cases occurring in large-scale randomized trials. Recent
reviews219 are encouraging about the safety of long-term
lipid-lowering therapy.
There is no predictive value of routine repeat CK testing for
rhabdomyolysis since the test can rise with muscle injury or
excess muscular exercise. However, CK must be assessed immedi-
ately in patients, especially the elderly, presenting with muscle
pains and weakness, and treatment stopped if .5 times the
ULN. In patients whose liver function tests rise above three
times the ULN, explanations such as alcohol ingestion or non-
alcoholic fatty liver disease should be sought and the levels moni-
tored. If levels remain elevated, then statins should be stopped but
may be cautiously re-introduced under monitoring after levels have
returned to normal. There is limited evidence to suggest that some
statins have more likelihood of being associated with muscle symp-
toms (but not CK change), or liver enzyme changes.
Table 33 summarizes the recommendations for monitoring lipids
and enzymes in patients on lipid-lowering therapy.
12. How to improve adherence to
lifestyle changes and compliance
with drug therapy
No smoking, healthy eating, and being physically active are the
foundations of preventive cardiology. These lifestyles are most
effectively achieved through formal programmes of preventive
care; such programmes are also more appropriate for initiating
and up-titrating drug therapies, achieving the treatment goals,
and adherence over the long-term which in turn improves event-
free survival.220 However, in everyday care, statins are usually pre-
scribed at the lowest dose and often not up-titrated to achieve
goals. In addition, adherence over the long term is poor, with up
to a third of patients or more stopping their statin treatment
within a year. Not up-titrating the dose of statin, and poor adher-
ence to this therapy, are the main reasons why over half of all cor-
onary patients, and four out of five of all high risk patients, are not
achieving the lipid goals and, as a consequence, are not achieving
the maximum benefits of these preventive strategies.221
So, the challenges for clinical practice are to initiate treatment in
both vascular patients and those at high risk of developing CVD,
up-titrate the dose to achieve the lipid goals wherever feasible,
and achieve adherence.
Most of the problems related to adherence to lifestyles are cur-
rently assumed to be similar to those related to compliance with
lipid-lowering drug therapy. Two of the most important factors
contributing to poor adherence are undoubtedly the asymptomatic
and lifelong nature of the disease. Other potential determinants of
adherence may be related to:
† demographic factors such as age and education
† the patient’s understanding and perception of dyslipidaemia
† the healthcare provider’s mode of delivering treatment
† the relationships between patients and healthcare professionals
† influences from the health systems, and
† complex chronic drug regimens.
Poor socioeconomic status, illiteracy, and unemployment are
important risk factors for poor adherence. Other important
patient-related factors may include understanding and acceptance
of the disease, perception of the health risk related to the
disease, awareness of the costs and benefits of treatment, and
active participation in monitoring and decision-making in relation
to management of the disease.222
In Table 34 some hints are given that may help improve patient
adherence to lifestyle changes.
The responsibility for adherence must be shared between the
healthcare provider, the patient, and the healthcare system.
Table 34 Hints to help adherence to lifestyle changes
Table 35 Tips to help compliance with multiple drug
therapies
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Good relationships between the patients and their healthcare pro-
viders are therefore imperative for good adherence. Empathetic
and non-judgemental attitude and assistance, ready availability,
and good quality of communication and interaction are some of
the important attributes of healthcare professionals that have
been shown to be determinants of the adherence of patients.223
Issues related to health systems also play an important role in
the promotion of adherence. In most low income countries,
supplies of medications are limited and they often have to be
bought out-of-pocket. Strategies for improving access to drugs
such as sustainable financing, affordable prices, and reliable
supply systems have an important influence on patient adherence.
Some of the better recognized determinants of adherence to
hypolipidaemic therapy are related to aspects of the drug treat-
ment itself, and include drug tolerability, regimen complexity,
drug costs, and treatment duration. In Table 35 some tips are
given that may help improve compliance with multiple drug
therapies.
The complexity of the regimen is, for instance, a treatment-
related factor that has been identified as a possible cause of
poor adherence. Frequency of dosing, number of concurrent medi-
cations, and changes in medications are some of the factors that
contribute to the complexity of a regimen, and these have been
investigated in many observational studies. Fewer daily doses of
drugs, monotherapies, and fewer changes in medications have all
been associated with better adherence.
Until better insight into adherence is obtained, multifaceted
measures to assist patients to follow treatment with
lipid-lowering drugs have to be adopted. Healthcare providers
need to be made aware of the low rates of adherence of
patients with dyslipidaemia. They should receive training on
how to counsel patients in a constructive and non-judgemental
manner, with the primary goal of helping the patient to
adhere better to the treatment schedule.
Patients need to understand the importance of maintaining
lipid control during the day and to use their drugs rationally.
Furthermore, they need to learn how to deal with missed
doses, how to identify adverse events, and what to do when
they occur.
While many interventions (e.g. education in self-management;
pharmacy management programmes; nurse, pharmacist, and
other non-medical health professional intervention protocols;
counselling; behavioural interventions; follow-up; and reminders)
have been shown to be effective in significantly improving adher-
ence rates,224 they have tended to be used alone. A single factor
approach might be expected to have limited effectiveness if the
factors determining adherence interact and potentiate each
other’s influence, as they are likely to do.
The most effective approaches have been shown to be
multilevel—targeting more than one factor with more than one
intervention. Several programmes have demonstrated good
results using multilevel team approaches. In fact, adequate evidence
exists to support the use of innovative, modified healthcare system
teams rather than traditional, independent physician practice and
minimally structured systems.221
Most of the statements in these guidelines are supported
by published evidence. Only a minority of the publications that
support the written text can be listed in the following abridged
reference list of the guidelines. A full list of the references is
available on the ESC website (www.escardio.org/guidelines).
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